netFormulary
 Report : A-Z of formulary items 12/11/2019 19:17:09
[Back]
 
Section Name Details
01.05.03 Vedolizumab 

See NCL treatment pathways for place in therapy in adults (JFC April 2019). Approved for paediatric use (JFC January 2018).

Provider notes

  • NMUH:
    • Positive NICE TA. This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • Restricted to consultant gastrenterologists for NICE approved indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA342 June 2015.
14.04 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
20 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
  • WH:
    • Non-formulary
05.03.01 Abacavir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Abacavir + Lamivudine 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL:
    • As per HIV guidelines
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Abacavir + Lamivudine + Zidovudine Trizivir®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • As per HIV guidelines
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.03 Abatacept 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Rheumatologists ONLY.
    • Check MHRA Drug Safety Updates.
    • See links below.
  • RFL:
    • Approved for Rheumatoid Arthritis, in line with NICE guidance.
    • Approved for Psoriatic Arthritis.
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY.
  • UCLH:
  • WH:
    • As per NICE TA and above
08.01.05 Abemaciclib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Abiraterone 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. To be prescribed as per NICE guidance
    • See links below
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
04.10.01 Acamprosate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Requires psychiatrist approval. For use in accordance with NICE CG115.
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Acarbose 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Acemetacin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Rheumatology only.
02.08.02 Acenocoumarol 

Provider notes

  • NMUH:
    • Restricted for patients allergic to Warfain only.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Restricted for patients allergic to warfarin only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Acetazolamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Adjunctive therapy for Open Angle Glaucoma And Ocular Hypertension

Provider notes

  • NMUH:
    • See link below
    • Immedidate release and modified release formulations are both available
  • RFL:
    • Immediate release only
  • RNOH: 
    • Immediate release only
  • UCLH:
  • WH:
    • Immediate release only
11.08.02 Acetylcholine intra-ocular irrigation Miochol-E®, Miphtel®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
03.07 Acetylcysteine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Respiratory consultants only
    • Injection (200mg/ml) can be used orally
    • Tablets 600mg also available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
18 Acetylcysteine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Acetylcysteine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.01 Acetylcysteine 5% + Hypromellose 0.35% eye drops Ilube®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.01 Acetylcysteine eye drops - preservative free 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Acetylcysteine 5% preservative free drops (10mL) is an unlicensed special and restricted to Ophthalmology.
05.03.02.01 Aciclovir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.03.03 Aciclovir 3% eye ointment 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.10.03 Aciclovir 5% cream 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Acitretin 

Provider notes

  • NMUH:
    • Restricted to Dermatology
  • RFL:
    • Restricted to Dermatology
    • 10mg and 25mg capsules available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Dermatology use only
A5.03.03 Actisorb Silver 220 

Provider notes

  • NMUH:
    • We stock 10.5 cm x 10.5 cm. To be used on the recommendation of the Tissue Viability Nurse only.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
18 Activated charcoal 

Provider notes

  • NMUH:
    • Carbomix and Charcodote available
  • RFL:
    • Actidose-Aqua Advance, Carbomix, Charcodote available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.03 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update
  • RFL:
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to consultant gastroenterologists 
    • NICE TA187 and TA329 applies
    • JFC (Oct 17): Approved for fistulising Crohn's disease in patients not able to receive infliximab.
10.01.03 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TA)
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH: 
    • Check MHRA Drug Safety Updates
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists
    • See links below
  • RFL:
    • Approved for use in Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis and Hidradenitis Suppurativa (NHSE)
  • RNOH:
    • Restricted to Rheumatology Consultants Only
  • UCLH:
  • WH:
    • As per NICE TA and above
11.99.99.99 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Dermatologists for NICE approved indications.
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for Psoriasis and Hydradenitis Suppurativa (NHSE)
    • Homecare available - usually after 1 month
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.06.01 Adapalene 0.1% + Benzoyl peroxide 2.5% gel Epiduo®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for Dermatology for acne vulgaris
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Prescribing by Consultant Dermatologists only for acne
13.06.01 Adapalene 0.1% cream Differin®

Approved for acne (JFC April 2016)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See indication above
05.03.03.01 Adefovir Dipivoxil 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal BUT IS NOT LISTED IN THE TRUST FORMULARY AS AN ALTERNATIVE NICE APPROVED MEDICINE IS USED.
  • RFL:
    • Restricted to Hepatology/Virology
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.03.02 Adenosine 6mg/2mL injection Adenocor®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.07.03 Adrenaline 1:10,000 (100 mcg/1 ml) injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.04.03 Adrenaline 1:10,000 (100 mcg/1 ml) injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
03.04.03 Adrenaline 1:1000 (1 mg/1 ml) injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of epinephrine 1 in 1,000 units Min-I-Jet injection is reserved for treatment of anaphylaxis in children < 15 kg in weight.
03.04.03 Adrenaline autoinjector Emerade®

Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)

 

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.04.03 Adrenaline autoinjector EpiPen®

Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
A5.02.07 Advadraw  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A5.02.03 Advazorb Border 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Afatinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Aflibercept infusion Zaltrap®

Provider notes

  • NMUH:
    • Non-formulary
    • See MHRA Drug Safety Update
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.02 Aflibercept intraocular injection Eylea®

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultant Ophthalmologists ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • To be prescribed by consultant opthalmologists only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.08.01 Agalsidase Alfa and Beta Fabrazyme®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Agalsidase Alfa and Beta Replagal®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Ajmaline 

Provider notes

  • NMUH:
    • Restricted to Consultant Cardiologists ONLY.
    • Ajmaline 50mg in 10mL injection - available from 'special-order' manufacturers or specialist importing companies.
    • See link below
  • RFL:
    • Approve for diagnosis of Brugada syndrome (August 2016)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.05.01 Albendazole 

Provider notes

  • NMUH:
    • For use for named patients only
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.02.02.02 Albumin Solution 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available via the blood bank
  • RNOH:
    • Available from Pathology
  • UCH approvals:
  • WH:
    • No restriction stated
08.01.05 Alectinib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic).
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 Alemtuzumab Lemtrada®

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
06.06.02 Alendronic Acid 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.06.04 Alfacalcidol One-Alpha®

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Store in refrigerator
  • UCLH:
  • WH:
    • No restriction stated
15.01.04.03 Alfentanil 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.04.01 Alfuzosin immediate release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.01 Alfuzosin modified release 

Provider notes

  • NMUH:
    • Restricted to Urology Department, second line use only.
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of alfuzosin is reserved for the Urology Department only
09.08.01 Alglucosidase Alfa Myozyme®

Provider notes

  • RFL:
    • Restricted to the lysosomal storage disorders unit
03.04.01 Alimemazine tabs/solution 

Not recommended for any indication - do not prescribe (JFC November 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
02.12 Alirocumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • Restricted to Lipid Clinic
    • Prescriptions are supplied monthly for first 4 months then 3 monthly.  Homecare service also available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.05.01 Alitretinoin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety updates
  • RFL:
    • For severe chronic hand eczema in line with NICE guidance
    • Females of childbearing potential must meet the requirements of the pregnancy prevention programme (PPP) - maximum 30 days supply at at time
    • Alitretinoin prescriptions should be restricted to a 12 week supply for men and post menopausal women
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.01 Alitretinoin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Alitretinoin for pityriasis rubra pilaris
Evaluation at RFL site only (August 2016)

10.01.04 Allopurinol 

Provider notes

  • NMUH:
    • See link(s) below
  • RFL:
    • No restriction stated
  • RNOH:
    • First choice for long-term control of gout
  • UCLH:
  • WH:
    • No restriction stated
09.06.05 Alpha Tocopheryl Acetate 

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Oral suspension and injection 100mg/2ml kept at the RFH.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.05 Alprostadil intracavernous injection Caverject®

GP-Red Red If used for non-SLS indications

Provider notes

  • NMUH:
    • Red List Medicine – Hospital Only Prescribing
  • RFL:
    • Restricted to Urology and Endocrinology consultants
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Inj 20 micrograms only
07.04.05 Alprostadil intracavernous injection Viridal® Duo

GP-Red Red If used for non-SLS indications

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Urology and Endocrinology Consultants
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.04.05 Alprostadil urethral stick MUSE®

GP-Red Red If used for non-SLS indications

Provider notes

  • NMUH:
    • Red List Medicine – Hospital Only Prescribing Restricted to Consultants in Urology and Sexual Health (St. Ann's) use only.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.10.02 Alteplase 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted for use in Pulmonary Embolism (PE).
  • RFL:
    • Restricted to vascular surgery and for use in the treatment of PE
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • For massive PE and PE causing cardiac arrest
20 Alteplase 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for:
      • Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (JFC July 2018)
      • Paget-Schroetter Syndrome
    • Not approved for:
      • Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (JFC July 2018)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for:
      • Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (UMC June 2018)
      • Upper Limb Central Venous Catheter (CVC) Related Thrombosis as last-line therapy (UMC June 2018)
    • Not approved for:
      • Paget-Schroetter Syndrome- Refer patient to RFH (UMC June 2018)
      • Stent rethrombosis (UMC June 2018)
      • Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (UMC June 2018)
  • WH:
    • Non-formulary
21.01 Alteplase 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Alteplase for complicated visceral thrombosis
Evaluation at RFL site only (July 2014)

13.12 Aluminimum chloride 20% Anhydrol Forte®

Provider notes

  • NMUH:
    • Suitable for use in children, adults and the elderly. NOT suitable for use in pregnancy and lactation.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.12 Aluminimum chloride 20% Driclor®

Provider notes

  • NMUH:
    • Suitable for use in pregnancy and lactation.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Aluminium acetate 8% or 13% ear drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.01.01 Aluminium hydroxide Alu-Cap®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.02.02 Aluminium Hydroxide Alu-Cap®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:
    • Alu-Cap can be used as a phosphate binding agent in chronic renal failure. The dose is 4 to 20 capsules daily in divided doses depending on the phosphate level of the patient.
  • RFL:
    • Restricted to renal patients only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Renal patients only
01.01.01 Aluminium hydroxide + Magnesium hydroxide + Simeticone Maalox Plus®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Amantadine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • No restriction stated
05.03.04 Amantadine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Virology/Microbiology/ID approval only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Microbiologist approval only
02.05.01 Ambrisentan 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding approval required. Restricted to the treatment of pulmonary hypertension
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
11.03.01 Amikacin 1.5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to opthalmology
    • Intravitreal use - kit available - seek pharmacy advice
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Intravitrial use - this is an unlicensed special and restricted to Ophthalmology.
24.01 Amikacin 2.5% eye drops 

unlicensedunlicensed

MEH: Bacterial & Mycobacteria keratitis

05.01.04 Amikacin injection 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
  • RFL:
    • Refer to amikacin prescribing guidelines in Microguide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
02.02.03 Amiloride Hydrochloride 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.08 Aminolevulinic acid  

Secondary care notes

  • RFL approvals
    • First line treatment of actinic keratosis and basal cell carcinoma
    • Ameluz ®
03.01.03 Aminophylline Phyllocontin Continus®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.01.03 Aminophylline IV 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.01.09 Aminosalicylic acid 

Provider notes

  • NMUH:
    • Available from 'special order' manufacturers
  • RFL:
    • Available from 'special order' manufacturers
    • Restricted to ID / microbiology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.03.02 Amiodarone 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.02.01 Amisulpride 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only.
04.03.01 Amitriptyline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral solution available as 25 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Depression
  • BEHMT approvals:
    • Depression
04.07.03 Amitriptyline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • See link below
    • Oral solution available as 25 mg/5mL 
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.02 Amitriptyline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.06.02 Amlodipine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.10.02 Amorolfine 5% nail lacquer 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted antimicrobial agent.
    • Only the nail lacquer is available at The Royal Free Hospital
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.01.03 Amoxicillin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 125 mg/5mL and 250 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
11.03.02 Amphotericin 0.15% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology for use in candida fungal infections and keratitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
05.02 Amphotericin infusion Fungizone®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Not for intravenous use
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for:
      • Cryptococcosis – treatment (Restricted to Microbiology approval)
      • Serious fungal infections (Restricted to Microbiology approval for intraventricular disease)
  • WH:
    • Non-formulary
05.02 Amphotericin liposomal infusion AmBisome®

Provider notes

  • NMUH:
    • As per Trust Guidelines
  • RFL:
    • Restricted to OLT prophylaxis (2nd transplant/hepatic artery thrombosis)
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
09.01.04 Anagrelide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • See links below
  • WH:
    • No restriction stated
10.01.03 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for adult-onset Stills disease in line with NHSE commissioning policy (JFC October 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for AOSD in line with NHSE policy (see below)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for Familial Mediterranean Fever, Pericarditis and DIRA (RFL only; JFC May 2016)
    • Prior funding approval required
    • Restricted to use by the Amyloidosis centre only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for gout for patients who are hospitalised and refractory to all other treatments. The usual dose is 100 mg daily subcutaneously for 3 days (JFC September 2014) 

Provider notes

  • NMUH:
    • To be prescribed/ recommended by Rheumatology Consultants ONLY
    • Anakinra has been approved for gout. This is an unlicensed indication and the recommended dose is 100mg by subcutaneous injection ONCE a day for 3 days.
    • Check MHRA Drug Safety Updates
  • RFL:
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY.
    • Unlicensed for the treatment of gout, 100mg daily for 3 days
  • UCLH:
  • WH:
    • Restricted to Rheumatology Consultants ONLY
20 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approval for chronic Granulomatous Disease (January 2013)
    • Prior funding approval required
    • Restricted to use by the Amyloidosis centre only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.01 Anastrozole 

Provider notes

  • NMUH:
    • Restricted to Oncology department use only.
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.02.04 Anidulafungin 

Approved for invasive candidiasis, subject to local Antimicrobial Committee approval (JFC February 2019).

Provider notes

  • NMUH:
    • To be used as per Trust antifungal guidelines
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Microbiology approval only
12.03.01 Antacid + Oxetacaine oral suspension 

Approved for oral mucositis post radiotherapy (JFC February 2019).

Provider notes

  • NMUH:
    • For oral mucositis and oesophageal lesions following radiotherapy. 
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.05.03 Anti-D (Rh0) Immunoglobulin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary.
    • It is available via the blood bank
  • RFL:
    • Not available through pharmacy - obtain from the blood bank
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Available from Haematology (Ext 5035)
02.11 Antithrombin III Kybemin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Antithymocyte immunoglobulin - rabbit Thymoglobuline®

Provider notes

  • RFL:
    • Resricted to renal team for the treatment of transplant rejection
01.07.02 Anusol-HC® 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Ointment and suppositories both stocked
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Ointment containing hydrocortisone 0.25%. Suppositories containing hydrocortisone acetate 10 mg
21.02 Apalutamide (free of charge) 

Patient-access scheme approved for non-metastatic castration resistant prostate cancer (JFC May 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.08.02 Apixaban 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA Drug Safety Update
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL:
    • As per NICE guidance
    • Follow NCL DOAC prescribing guide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • 2nd Choice DOAC - For Atrial Fibrillation / Stroke prevention.
04.09.01 Apomorphine 

Provider notes

  • NMUH:
    • Non-formulary
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
11.08.02 Apraclonidine ophthalmic solution Iopidine®

Provider notes

  • NMUH:
    • Apraclonidine 0.5% used short-term to delay laser treatment or surgery in patients with glaucoma not adequately controlled by another drug
    • See link below   
  • RFL:
    • 1% restricted to Opthalmology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Apraclonidine 1% preservative free is restricted to Ophthalmology
10.01.03 Apremilast 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for:

  • Psoriatic Arthritis (PsA; see NICE TA)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Rheumatologists ONLY
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • As per NICE guidance for PsA
  • RNOH:
    • Rheumatology Consultants ONLY
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Apremilast 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH: 
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below.
    • Check MHRA Drug Safety Updates.
  • RFL:
    • For the treatment of Psoriasis in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.06 Aprepitant 

Provider notes

  • NMUH:
    • Restricted to Oncology Consultants only
  • RFL:
    • Restricted to oncology and haematology only.
  • RNOH:
    • Restricted for severe emetogenesis.
    • Restricted to Dr Kofi Agyare
  • UCLH:
  • WH:
    • Reserved for the prophylaxis of nausea & vomiting associated with cisplatin (CINV)

 

A5.02.04 Aquacel  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Hydrocolloid dressing 10 cm * 10 cm (10), 15 cm * 15 cm(5)
13.02.01 Aquadrate® cream Urea 10%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Aqueous Cream BP 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.06.03 Arachis Oil Enema 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Requires gastroenterologist approval
  • UCLH:
  • WH:
    • Non-formulary
02.08.01 Argatroban 

Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per restrictions above
    • Haemophilia recommendation only
  • RNOH:
    • Requires Haematologist approval. See restriction above.
  • UCLH:
    • Restricted to consultant haematologists. For patients with severe renal impairment (CrCl<30ml/min)
  • WH approval:
    • Non-formulary
06.05.02 Argipressin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Non-formulary
04.02.01 Aripiprazole 

Intramuscular formulation (7.5mg/1mL) is approved for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder when oral therapy is not appropriate and where IM haloperidol is not recommended. (JFC January 2019)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but NOT routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information.
    • See links below
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Initiation with Psychiatry advice only
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
05.04.01 Artemether + Lumefantrine 

Provider notes

  • NMUH:
    • To be used as per the NMUHT Malaria Guidelines, see links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • First line for uncomplicated falciparum malaria, chloroquine-resistant non-falciparum malaria, and PO step down from IV artesunate
    • See link below
20 Artesunate 

Approved for severe falciparum malaria (November 2015) 

Provider notes

  • NMUH:
    • To be used on the recommendation of the Infectious Diseases Team or Microbiology according to the NMUHT malaria guidelines.
    • See link below
    • Available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Articaine hydrochloride + Adrenaline injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For dental use at BCF only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
07.04.03 Ascorbic Acid Vitamin C

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Acidification may prevent encrustation of indwelling catheters, excess mucus formation in bladder augmentation and urinary tract infections. Many patients find high dose ascorbic acid unpalatable and may prefer to take cranberry juice drinks that are now widely available in the high street.
09.06.03 Ascorbic Acid Vitamin C

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Tablets 50mg,100mg, 200mg and 500mg
    • Injection 500mg
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
A5.03.03 Askina Calgitrol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Use restricted to Tissue Viability Nurse (TVN) specialist
02.09 Aspirin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • See NCL JFC summary of antiplatelet options in cardiovascular disease for specific indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.01 Aspirin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Chronic intractable daily headache (Aspirin 500mg injection - unlicensed - Restricted to neurology)
    • Mild to moderate pain
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Atazanavir 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by HIV team only
  • RFL:
    • As per HIV guidelines
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Atazanavir + cobicistat Evotaz®

Provider notes

  • NMUH:
    • To be initiated by Consultants in HIV Medicine only
  • RFL:
    • HIV Medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
02.04 Atenolol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Atenolol injection restricted to cardiology and ITU only.
  • RNOH:
    • Tablets available. Oral syrup available as 5 mg/mL
  • UCLH:
  • WH:
    • Tabs 50 mg, 100 mg; Syrup 25 mg/5 ml
08.01.05 Atezolizumab  

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 520
04.04 Atomoxetine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the Child & Adolescent Mental Health Service only  
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As per NICE TA98 / CG87
02.12 Atorvastatin 

Provider notes

  • NMUH:
    • See NCL JFC Statins Guideline
  • RFL:
    • Use is restricted to HIV, Renal, and lipid clinic patients, as well as suspected simvastatin intolerance and drug interactions. 
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • No restriction stated
07.01.03 Atosiban 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • See links below
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Atosiban is to be used only in accordance with protocol
05.04.08 Atovaquone 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Microbiology use only
05.04.01 Atovaquone + Proguanil 

Provider notes

  • NMUH:
    • To be used as per the NMUHT Malaria Guidelines
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.05 Atracurium besilate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Store in refrigerator 
  • UCLH:
  • WH:
    • No restriction stated
A5.01.01 Atrauman  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.03.03 Atrauman AG 

Provider notes

  • NMUH:
    • 10cm x 10 cm is available on the recommendation of the Tissue Viability Nurse only.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.05 Atropine eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Atropine 0.5% eye drops are not kept.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Eye-drops 0.5% not available
11.05 Atropine eye drops - single use 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.01.03 Atropine injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.01.03 Atropine Minijet® injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.02 Atropine tabs 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.04 Avaxim® Hepatitis A vaccine Single Component

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Aveeno® Bath Oil 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

#Secondary care notes

  • NMUH:
    • Non-formulary
  • RFL:
    •  Only approved for above indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

 

13.02.01 Aveeno® cream 

Provider notes

  • NMUH:
    • Non-formulary 
  • RFL: 
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Avelumab 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.04.05 Aviptadil + phentolamine Invicorp®

Erectile dysfunction in men who have failed to respond to oral PDE5i (sildenafil and tadalafil) and intracavernosal/urethral alprostadil. Secondary care initiation, primary care continuation (SLS only) (JFC November 2017)

Provider notes

  • NMUH:
    • To be prescribed by Urology Consultants ONLY. To be used as a second line option after treatment failure or intolerance with oral PDE5i (tadalafil or sildenafil) and intracavernosal/ urethral alprostadil.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Approved by NCL as 2nd line treatment for erectile dysfuntion if alprostadil fails (JFC November 2016)
08.01.05 Axitinib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.03 Azacitidine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Approved for Haematology for MDS, CMML and AML in line with NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Azathioprine should be initiated only by the Gastroenterology team for difficult cases. FBC and LFT monitoring is required.
01.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for autoimmune hepatitis (JFC February 2018)

Provider notes

  • NMUH:
  • RFL:
    • See indication above
  • RNOH:
  • UCLH:
  • WH:
    • Specialist initiation, continuation in primary care
08.02.01 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Regular monitoring of FBC and LFTs is required.
10.01.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for Pemphigus Vulgaris (PV), Mucous membrane pemphigoid (MMP), Recurrent apthous stomatitis (RAS), Oral lichen planus (OLP), Oral Crohn’s disease (OCD) (JFC June 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See above
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • Non-formulary
13.06.01 Azelaic acid 15% gel Finacea®

Provider notes

  • RFL:
    • Restricted to Dermatology
13.06.01 Azelaic acid 20% cream Skinoren®

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.02.01 Azelastine + Fluticasone nasal spray Dymista®

Approved for allergic rhinitis when 1st line betamethasone monotherapy and 2nd line fluticasone monotherapy have failed (JFC September 2015)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Approved for the indication outlined above
12.02.01 Azelastine nasal spray Rhinolast®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the allergy clinic only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of azelastine hydrochloride nasal spray is restricted to ENT department only
11.03.01 Azithromycin 15 mg/g eye drops 

Provider notes

  • RFL:
    • Restricted to Opthalmology.
    • Approved for use in ocular chlamydia infections, blepharitis, paediatrics and adults.
    • Azithromycin 1.5% single use eye drops                                                
05.01.05 Azithromycin tabs/caps/suspension 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Azithromycin is a restricted antimicrobial
    • Refer to Microguide for agreed indications, all other indications require microbiology approval
    • Used for prophylaxis of Mycobacterium avium intracellulare in HIV
  • RNOH:
    • Oral suspension available as 200 mg/5mL
  • UCLH:
  • WH:
    • Suspension is reserved for Paediatric and Neonatal use only
24.01 Azithromyin 1.5% single use eye drops 

MEH: Ocular Chlamydia infections; blepharitis

05.01.02.03 Aztreonam 

Provider notes

  • NMUH:
    • Consultant Microbiologist recommendation only
  • RFL:
    • Microbiology approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.02.02 Baclofen Intrathecal 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Unlicensed - Intrathecal baclofen 1000 micrograms/mL, 2000 micorgrams/mL and 3000 micrograms/mL are unlicensed products
  • UCLH:
  • WH:
    • Non-formulary
10.02.02 Baclofen oral 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral liquid available as 5 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
13.02.01.01 Balneum® bath oil 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only approved for above indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Balneum® cream Urea 5%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Balneum® Plus bath oil 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for ichthyosis and epidermolysis bullosa only (JFC January 2019)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Dermatology use ONLY
13.02.01 Balneum® Plus cream Urea 5%

Provider notes

  • RFL:
    • 1st line urea containing emollient
10.01.03 Baricitinib 

Approved for:

  • Rheumatoid arthritis (see NICE TA)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
    • See link below
  • RFL:
    • As per NICE guidance for the treatment of RA
  • RNOH:
    • Rheumatology Consultants Only
  • UCLH:
  • WH:
    • As per NICE TA and above
08.02.02 Basiliximab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but service is not offered at NMUH.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Prior funding required for treatment of lymphoma with radiolabelled basiliximab Approved for Renal transplant patients.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 BCG bladder instillation OncoTICE®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 BCG bladder instillation ImmuCyst®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.04 BCG diagnostic agent - Intradermal injection 

Provider notes

  • NMUH:
    • Tuberculin Purified Protein Derivative (PPD)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Tuberculin PPD SSI is an unlicensed product
14.04 BCG vaccine - Intradermal injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • BCG Vaccine SSI is an unlicensed product
12.02.01 Beclometasone dipropionate 50mcg/spray nasal spray 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.02 Beclometasone dipropionate inhaler (pMDI) Clenil Modulite®

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • RNOH:
    • Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • UCLH:
  • WH:
    • First choice
    • CFC-free beclometasone inhalers are not equipotent and should be prescribed by brand name
    • Inhaler 50 micrograms, 100 micrograms, 200 micrograms, 250 micrograms/metered inhalation ONLY
03.02 Beclometasone dipropionate inhaler (pMDI) Qvar®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • MDI and Autohaler available
  • RNOH:
    • Restricted for continuation of treatment. Qvar® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • UCLH:
  • WH:
    • Turbohalers, Accuhalers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
    • Inhaler CFC-Free 50 micrograms, 100 micrograms/metered inhalation (Qvar) & Qvar Autohaler 50 micrograms, 100 micrograms, /metered inhalation ONLY
03.02 Beclometasone diproponate + Formoterol inhaler (pMDI) Fostair®

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Dry powder (Nexthaler®) and MDI available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Fostair should only be supplied when prescribed by, or on the recommendation of, the Respiratory Team. This is to ensure that it is prescribed appropriately.
05.01.09 Bedaquiline 

Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for XDR-TB and MDR-TB in line with NHSE policy
    • Restricted to ID team only
  • RNOH:
    • Non-formulary  
  • UCLH:
    • Pulmonary multidrug-resistant tuberculosis in line with NHS England policy, restricted to TB team
  • WH:
    • As above
03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®

Provider notes

  • NMUH:
    • Non-formulary.
    • This medicine has a positive NICE Technology Appraisal, however, VENOM IMMUNOTHERAPY SERVICE IS NOT PROVIDED AT NMUH. 
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted Item Restricted
  • UCLH:
  • WH:
    • No restriction stated
10.01 Belimumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH - for intiation at specialist centres.
    • See MHRA Drug Safety Update.
  • RFL:
    • Approved for use in the treatment of SLE in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE technology appraisal.
    • See link below.
08.01.01 Bendamustine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Approved for relapsed low grade NHL and MM (3rd line) as per CDF criteria
    • Approved for use as per NICE TA216
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
    • For relapsed multiple myeloma in line with Cancer Drugs Fund only
  • WH:
    • As per NICE TA(s)
02.02.01 Bendroflumethiazide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.02.01 Benperidol 

Provider notes

  • NMUH:
    • Non-formulary  
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.09 Benzalkonium chloride 0.5% shampoo Dermax®

Provider notes

  • RFL:
    • Dermatology only
20 Benzathine benzylpenicillin 

Provider notes

  • NMUH:
    • Used in the treatment of early syphilis and late latent syphilis
    • Benzathine Benzylpenicillin 2.4 mega unit injection, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Used in the treatment of early syphilis and late latent syphilis
    • Benzathine Benzylpenicillin 2.4 mega unit injection, available from ‘special-order’ manufacturers or specialist importing companies
      RNOH approvals
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.10.02 Benzoic Acid Ointment, Compound BP Whitfield's ointment

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.06.01 Benzoyl peroxide - Topical PanOxyl®

 

Provider notes

  • NMUH:
    • Formulary options:
      • Aquagel 2.5% & 10%
      • Gel 5%
    • NON-FORMULARY
      • Aquagel 5% 
      • Cream 5% 
      • Gel 10%
      • Panoxyl wash
  • RFL:
    • 2.5% and 5% gel available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.06.01 Benzoyl peroxide 5% + Clindamycin 1% gel Duac® Once Daily

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Duac gel is restricted to Dermatology
12.03.01 Benzydamine Difflam®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Mouthwash and Spray available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.10.04 Benzyl Benzoate Application BP 25% 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.01.01 Benzylpenicillin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.06 Betahistine Dihydrochloride 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.02.02 Betamethasone  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone dipropionate 0.05% - Topical Diprosone®

Provider notes

  • NMUH:
    • Diprosone cream and Diprosone ointment are FORMULARY.
    • Diprosone lotion is NON-FORMULARY.
  • RFL:
    • ONLY ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Betamethasone dipropionate 0.05% + Salicylic acid 3% - Topical Diprosalic®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Ointment and Scalp Application available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone dipropionate 0.064% + Clotrimazole 1% - Topical Lotriderm®

Provider notes

  • NMUH:
    • Restricted to Dermatology department use ONLY
  • RFL:
    • Dermatology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.04.01 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
12.01.01 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated

 

12.02.03 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.01.01 Betamethasone sodium phosphate 0.1% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Not applicable 
  • UCLH:
  • WH:
    • No restriction stated
12.02.01 Betamethasone sodium phosphate 0.1% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.04.01 Betamethasone sodium phosphate 0.1% drops, 0.1% ointment 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.03.01 Betamethasone soluble tablets 

Approved for oral mucosal inflammatory disease (JFC March 2018)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above

 

06.03.02 Betamethasone systemic injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Inj 4 mg/1 ml ONLY
06.03.02 Betamethasone tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone valerate 0.025% - Topical Betnovate-RD®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • cream and ointment available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone valerate 0.1% - Topical 

Provider notes

  • NMUH: 
    • When Betnovate cream or ointment are requested/prescribed, the non-proprietary version, betamethasone valerate 0.1% cream or ointment will be supplied.
    • When Betnovate scalp application is prescribed/requested, Betacap (betametasone valerate 0.1%) scalp application will be supplied.
  • RFL:
    • Only Cream, Ointment and Scalp application and foam available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated

 

13.04 Betamethasone valerate 0.1% + Clioquinol 3% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Betnovate C
    • Cream and Ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Betamethasone valerate 0.1% + Fucidic acid 2% - Topical Fucibet®

 Provider notes

  • NMUH:
    • Fucibet cream is FORMULARY
    • Fucibet lipid cream is NON-FORMULARY
  • RFL:
    • ONLY the cream available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Dermatology use ONLY
    • Cream ONLY available
13.04 Betamethasone valerate 0.1% + Neomycin 0.5% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

 

13.04 Betamethasone valerate 0.1% scalp application Betacap®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.04 Betamethasone valerate 0.12% scalp application Bettamousse®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Betaxolol 0.5% solution eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Bevacizumab 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
    • Discuss with cancer pharmacy team before prescribing
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.02 Bevacizumab intravitreal injection 

Approved for:

  • Neovascular glaucoma (single-dose intravitreal) as an adjunct to panretinal photocoagulation (January 2017)
  • Pre-operative adjunct to diabetic vitrectomy (MEH only; April 2017)
  • Coats' disease and Familial exudative vitreoretinopathy (FEVR) (November 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in neovascular glaucoma as an adjunct to panretinal photocoagulation
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
02.12 Bezafibrate 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Immediate and modified release
    • No restriction stated
  • RFL:
    • Immediate and modified release
    • Restricted to Lipid Clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Bicalutamide 

Provider notes

  • NMUH:
    • Restricted to Consultant Oncologist and Urologist use only.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Bicalutamide 150mg is reserved for the treatment of locally advanced prostate cancer where it is important to maintain sexual potency.
11.06 Bimatoprost 0.01% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.06 Bimatoprost 0.03% + Timolol 0.1% eye drops Ganfort®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Bimatoprost 0.03% + Timolol 0.1% eye drops - preservative free Ganfort®

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.

Combination therapies to be used when compliance/cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Bimatoprost 0.03% eye drops- single use 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Binimetinib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Biotin  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.03.05 BioXtra® oral gel 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Biphasic Insulin Lispro Humalog® Mix25, Humalog® Mix50

Approved for:

  • First choice biphasic analogue insulin in Type 2 diabetes. See NCL guideline for insulin in Type 2 diabetes guideline.
  • Type 1 diabetes


Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Biphasic Isophane Insulin Humulin® M3

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Biphasic Isophane Insulin Insuman® Comb 15, Insuman® Comb 25, Insuman® Comb 50

First choice biphasic human insulin. See NCL guideline for insulin in Type 2 diabetes guideline.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
01.06.02 Bisacodyl 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Please note: Suppositories 10 mg, Paediatric suppositories 5 mg only
01.03.03 Bismuth subsalicylate Pepto-Bismol®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for eradication of  H.Pylori, after first-line treatment and previous exposure to levofloxacin (JFC April 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.04 Bisoprolol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.08.01 Bivalirudin 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • NICE TA230 applies. Not routinely stocked at WH.
08.01.02 Bleomycin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.04 Boostrix-IPV 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Bortezomib injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY
    • See links below
  • RFL:
    • As per NICE guidance/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.05.01 Bosentan 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for digital ulceration in systemic sclerosis in line with NHSE Clinical Commissioning Policy A13/P/e (May 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • In line with NHSE clinical comissioning policy
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.05.01 Bosentan 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding approval required
    • Restricted to the treatment of pulmonary hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Bosutinib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.07.04 Botulinum toxin type A Botox®, Dysport®, Xeomin®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Xeomin brand only
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.02 Botulinum Toxin Type A Botox®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Positive NICE TA but service not offered at NMUH.
  • RFL:
    • Headaches and chronic migraine
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.03 Botulinum Toxin Type A Botox®, Dysport®, Xeomin®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary 
  • RFL:
    • Restricted to anal fissures, blepharospasm, facial palsy, hand spasticity patients with scleraderma, gastroparesis, female urology patients, headaches and chronic migraine and hyperhidrosis.
  • RNOH:
    • Dysport is first-line
  • UCLH:
  • WH:
    • Non-formulary
07.04.02 Botulinum toxin Type A Botox®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Approved for neurogenic bladder dysfunction for patients refractory to oral therapies (JFC January 2013) QUERY FUNDING

 

Provider notes

  • NMUH:
    • Botox brand only
    • Restricted to consultants Dr Yoong, Mr Nair and Mr Godbole for use in Overactive Bladder (OAB) only
  • RFL:
  • RNOH:
    • Restricted to Consultant Urologists only
  • UCLH:
  • WH:
    • See Botulinum Toxin Management Algorithm Diagram for direction of use
13.12 Botulinum toxin type A  

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • RFL:
    • Approved for use in dematology for the treatment of hyperhidrosis
    • Dysport® brand used
20 Botulinum toxin Type A Botox®, Dysport®, Xeomin®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Approved for Sphincter of Oddi Dysfunction  (JFC January 2013). QUERY funding

Provider notes

  • NMUH:
    • Xeomin is formulary when used in the treatment of achalasia (other brands and indications are non-formulary)
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.03 Botulinum Toxin Type B NeuroBloc®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted  
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Brentuximab vedotin 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL elecctronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
08.01.05 Brigatinib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Brimonidine 0.2% + Timolol 0.5% eye drops Combigan®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See link below
11.06 Brimonidine 0.2% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Not to be used for first-line treatment - see link below
13.06.01 Brimonidine 3 mg/g gel 

Approved for moderate to severe rosacea causing psychological distress or reduced quality of life - initiation by secondary care Dermatologist and continuation in primary care (JFC September 2014)

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Brinzolamide 0.1% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Use in line with NCL guideline below
11.06 Brinzolamide 1% + Timolol 0.5% eye drops Azarga®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Brodalumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
    • See links below
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Bromocriptine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • No restriction stated
06.07.01 Bromocriptine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 1mg, 2.5mg and 10mg strengths available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 1st Choice
01.05.02 Budesonide Entocort®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to left-sided ulcerative colitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.02 Budesonide Budenofalk®

Budenofalk® 2mg/dose rectal foam approved for active ulcerative colitis limited to the rectum and sigmoid colon as second-line (prednisolone retention enema is the first-line choice) (JFC October 2018).

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Tablets: Non-formulary
      Enema: See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
03.02 Budesonide + Formoterol inhaler (DPI) Symbicort® Turbohaler, DuoResp Spiromax®

Not approved as the sole inhaler for asthma (SMART), may be used twice daily for asthma (September 2015).

Provider notes

  • NMUH:
    • To be prescribed as per JFC Asthma / COPD guidelines
    • See links below
  • RFL:
    • To be prescribed as per JFC Asthma / COPD guidelines
  • RNOH:
    • Symbicort only
  • UCLH:
  • WH:
    • Non-formulary
12.02.01 Budesonide 100mcg/spray nasal spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • 64 microgram strength only 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.02 Budesonide inhaler Pulmicort® Turbohaler

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • See links below
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.02 Budesonide nebuliser suspension 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Nebulised budesonide should only be prescribed on the advice of a Consultant Paediatrician or a Respiratory Consultant.
20 Budesonide nebuliser suspension 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as second-line choice (after fluticasone inhaler) for eosinophilic oesophagitis in both adults and children. Dose should be dispersed in viscous suspending agent (e.g. Splenda slurry). Starting dose is 1 mg twice-daily for adults and children > 10 years old, 1 mg once-daily for children < 10 years old; down titrate dose for maintenance dosing (JFC February 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See local policy for information on use
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
02.02.02 Bumetanide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.02 Bupivacaine  

Approved for post-operative pain management following limb amputation for peripheral arterial disease to reduce post-operative opioid requirement (0.125% infusion via perineural stump catheter) (JFC September 2019). 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Inj 0.25% (25mg/10mL); 0.5% (50mg/10mL) only
15.02 Bupivacaine + Adrenaline 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.02 Bupivacaine + Fentanyl 

Provider notes

  • NMUH:
    • A ready-mixed bag of Fentanyl + Bupivicaine is available from Pharmacy
  • RFL:
    • Theatres: Bupivacaine 0.125% + Fentanyl 4micrograms/mL in NaCl 0.9% 480mL epidural bag
    • Labour: Bupivacaine 0.1% + Fentanyl 2micrograms/mL in NaCl 0.9% 15mL epidural syringe
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Bupivacaine + Glucose Marcain Heavy®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Buprenorphine patch '35', '52.5','70'  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Pain team initiation
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.02 Buprenorphine patch '5' and '10' 

Only buprenorphine patch ‘5’ and ‘10’ patches are available. Restricted for patients unable to take oral opioids due to swallowing difficulties / short bowel AND requiring a lower dose transdermal opioid dose than the 12 micrograms fentanyl patch (JFC March 2015).

Provider notes

  • NMUH:
    • See restriction above
  • RFL:
    • Transtec brand restricted to pain team only.
  • RNOH:
    • See restriction above
  • UCLH:
  • WH:
    • See restriction above
04.07.02 Buprenorphine sublingual tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.10.03 Buprenorphine sublingual tablets  

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary - see link below
    • For continuation ONLY
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.10.02 Bupropion 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT approvals:
    • Major depression where NICE recommended options are ineffective or not tolerated (off-label)
  • BEHMT approvals:
    • Non-formulary
06.07.02 Buserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to consultant gynaecologists only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Buserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to consultant gynaecologists only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Buserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.01.02 Buspirone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT approvals:
    • Anxiolytic
  • BEHMT approvals:
    • Anxiolytic
08.01.01 Busulfan infusion 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for conditioning prior to haematopoietic progenitor cell transplantation
  • WH:
    • No restriction stated
08.01.01 Busulfan tablets 

Provider notes

  • NMUH:
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
03.04.03 C1 Esterase Inhibitor Berinert®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Current preferred brand of C1-esterase inhibitor (September 2019)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Cabazitaxel 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
04.09.01 Cabergoline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
06.07.01 Cabergoline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Obs & Gynae Consultant use only
  • RFL:
    • Restricted to Endocrinology and Gynaecology.
    • 0.5mg, 1mg and 2mg strengths available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Cabergoline is reserved for use by Dr Moult and for suppression of lactation
08.01.05 Cabozantinib caps Cometriq®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for the treatment of medullary thyroid cancer
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Cabozantinib tabs Cabometyx®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance for the treatment of renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
21.01 Cacicol 

Non-healing corneal ulcers/ persistent epithelial defects. 
Under evaluation at MEH only (restricted to corneal eye disease service only, April 2017)

13.03 Calamine lotion 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Lotion BP 100 ml only
13.05.02 Calcipotriol 50mcg/g - Topical Dovonex®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Calcipotriol scalp application is restricted to Dermatology use only
13.05.02 Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical Dovobet®

Provider notes

  • NMUH:
    • Restricted to consultant Dermatologists ONLY
  • RFL:
    • Restricted to Dermatology ONLY
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For patients who fail separate topical steroid + vitamin D2 (e.g. calcipotriol)
    • Dovobet ointment restricted to Dermatology use ONLY
13.05.02 Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical foam Enstilar®

 

Approved after failure of combined topical steroid + vitamin D2 (e.g. Dovobet ointment) (JFC May 2017)

Provider notes

  • NMUH:
    • For Trunk & Limb psoriasis in patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
    • Restricted to dermatology use only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
    • Restricted to dermatology use only
06.06.01 Calcitonin (salmon) 

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
    • Store in a refrigerator
    • Allow to reach room temperature before subcutaneous or intramuscular use.
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Calcitriol 3mcg/g - Topical Silkis®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Dermatology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Calcitriol ointment is restricted to Dermatology use only
09.05.01.02 Calcitriol injection 

Provider notes

  • RFL:
    • Approved for percutaneous injection into the parathyroid gland for hyperparathyroidism if intolerant or unresponsive to oral therapy (November 2013)
09.06.04 Calcitriol oral 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.05.02.02 Calcium Acetate Phosex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to renal patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.06.04 Calcium and Ergocalciferol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
09.05.01.01 Calcium carbonate Cacit®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • WH:
    • Non-formulary
09.05.01.01 Calcium carbonate Calcichew®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.01.01 Calcium Carbonate Adcal®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.02.02 Calcium Carbonate Calcichew®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Calcichew is available on the Formulary for the management of hyperphosphotaemia in renal patients
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.02.02 Calcium Carbonate Adcal®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.02.02 Calcium Carbonate Calcium-500®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to renal patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.01.01 Calcium Chloride injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01 Calcium Folinate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.01.01 Calcium Gluconate 10% injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.01.01 Calcium Gluconate effervescent tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Calmurid® cream Urea 10%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A2.04.01.02 Calogen 

Provider notes

  • NMUH:
    • For disease-related malnutrition, malabsorption states or other conditions requiring fortification with a high-fat supplement with or without fluid and electrolyte restrictions Fat supplement without any electrolytes. Used for when protein, fluid or electrolytes restricted. Tolerating low volume of food. Can be used as a “medicinal dose” in combination with another supplement which is providing protein and calories
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Canagliflozin 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Restricted to Endocrinology
  • RNOH:
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH:
  • WH:
    • No restriction stated
08.02.04 Canakinumab 

Provider notes

  • RFL:
    • Approved for use by Professor Hawkins
02.05.05.02 Candesartan 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted Item Restricted
  • UCLH:
  • WH:
    • 1st choice A2RA/ARB for heart failure
02.09 Cangrelor 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Primary percutaneous coronary intervention (PPCI) who are intubated and cannot tolerate oral antiplatelets (JFC October 2017)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
08.01.03 Capecitabine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Update
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
    • See NICE TA and NHSE Commissioning Policy
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.02 Caplacizumab injection (free of charge) 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for thrombotic thrombocytopenia while available under a manufacturer-funded patient access scheme only (UCLH only; JFC September 2018)
  • WH:
    • Non-formulary
05.01.09 Capreomycin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Microbiology/ ID approval only (TB treatment)
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted to TB clinic or as per Microbiology advice
10.03.02 Capsaicin cream  

Provider notes

  • NMUH: 
    • 0.025% NON FORMULARY
    • 0.075% restricted to pain clinic use ONLY
  • RFL: 
    • 0.025% and 0.075% strength kept 
  • RNOH:
    • 0.025% restricted for use in accordance with the NICE guideline for osteoarthritis
    • See link(s) below
    • 0.075% NON FORMULARY
  • UCLH:
  • WH:
    • 0.025% restricted to the Rheumatology team. This strength of capsaicin cream is indicated for osteoarthritis only.
    • 0.075% restricted to pain clinic ONLY
10.03.02 Capsaicin patch 

JFC approved for neuropathic pain (January 2013)

Provider notes

  • NMUH:
    • Non-formulary  
  • RFL:
    • Restricted to RNOH patients @Hadley Wood
  • RNOH:
    • Restricted to named Consultants within the Chronic Pain team (Dr Roxy Zarnegar and Dr Tacson Fernandez) ONLY in accordance with DTC approval
  • UCLH:
  • WH:
    • Non-formulary
02.05.05.01 Captopril 

Provider notes

  • NMUH:
    • Only used for test dose
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of Captopril is reserved for situations where a short- acting preparation is necessary.
04.02.03 Carbamazepine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.03 Carbamazepine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • ???
  • RNOH:
    • Oral liquid available as 100 mg/5mL 
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Carbamazepine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Prescribe by brand when used for epilepsy.

Immediate release and modified release.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral liquid available as 100 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
07.01.01 Carbetocin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.02.02 Carbimazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.07 Carbocisteine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted Item Restricted. Capsules available. Oral syrup available as 250 mg/5mL
  • UCLH:
  • WH:
    • Carbocisteine to be initiated by respiratory team only
    • Liquid only available for patients with swallowing difficulties or for enteral feeding tube administration
11.08.01 Carbomers eye gel Viscotears®, GelTears® and others

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Carboplatin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Carboplatin + paclitaxel  

Approved as first-line treatment for advanced squamous cell carcinoma of anus  (JFC March 2019). 

Note: Carboplatin AUC5 day 1 of 28 day cycles + paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of 28 day cycles. 6 cycles (each cycle 28 days) 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Carboplatin + paclitaxel (CROSS) 

Approved as neo-adjuvant treatment before surgery for adenocarcinoma of the oesophagus or the gastro-oesophageal junction (JFC November 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
    • As above
  • WH:
    • Non-formulary
07.01.01 Carboprost 

Provider notes

  • NMUH:
    • Restricted to Obs and Gynae only. 
    • See link below
  • RFL:
    • Restricted to Obs and Gynae only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Carfilzomib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 457
11.08.01 Carmellose eye drops - single use 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
12.03.01 Carmellose Sodium Orabase®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.04 Carvedilol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
20 Carvedilol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for primary and secondary prevention of variceal bleeding for patients who do not respond to or cannot tolerate propranolol (August 2015)

Provider notes

  • NMUH:
    • See restrictions on use
  • RFL:
    • See restrictions on use
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • See restrictions on use
05.02.04 Caspofungin 

Provider notes

  • NMUH:
    • Microbiology consultant approval only
  • RFL:
    • Restricted to Haematology / Oncology as per policy
    • Microbiology approval required for all other indications.
  • RNOH:
    • Microbiology approval only
    • Store in a fridge
  • UCLH:
  • WH:
    • Reserved for prescribing by paediatric consultants only
A5.02.05 Cavi-Care 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.02.01 Cefalexin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Obstetrics and Paediatrics
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Oral suspension available as 250 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
05.01.02.01 Cefazolin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for surgical prophylaxis
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.02.01 Cefixime 

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine.
  • RFL:
    • Restricted to GUM
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.02.01 Cefotaxime 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
  • RFL:
    • Restricted to Neonatal and Hepatology unit
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Paediatrics and Neonatal use only
05.01.02.01 Ceftazidime 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
05.01.02.01 Ceftazidime + Avibactam  

Approved for the treatment of infections caused by non-MBL carbapenemase-producing aerobic Gram-negative organisms, that have proven susceptibly to ceftazidime-avibactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin, which cannot be used due to resistance or intolerance - Microbiology recommendation only (JFC August 2017)

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted antibiotics. Microbiology approval only
11.03.01 Ceftazidime 5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology. Approved for use in bacterial keratitis / ulcers
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
05.01.02.01 Ceftolozane + tazobactam 

Approved for multi-resistant Gram-negative organisms that have proven susceptibly to ceftolozane-tazobactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin (JFC September 2016)

Provider notes

  • NMUH:
    • Microbiology recommendation ONLY
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted antibiotics. Microbiology approval only
05.01.02.01 Ceftriaxone 

Provider notes

  • NMUH:
    • Restricted to use in paediatrics for sepsis and meningitis
  • RFL:
    • See Microguide for agreed indications
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
05.01.02.01 Cefuroxime 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
    • Injection is formulary
    • Tablets are non-formulary
  • RFL:
    • Restricted to Obstetrics and Ophthalmology
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
11.03.01 Cefuroxime 5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology. Approved for use in bacterial keratitis / ulcers
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
11.03.01 Cefuroxime intracameral injection Aprokam®

Approved for prophylaxis post-cataract surgery (June 2013)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Celecoxib 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For Rheumatology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Celiprolol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for vascular Ehlers-Danlos syndrome (JFC April 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Ceritinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
10.01.03 Certolizumab pegol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines (see links below).
    • Restricted to Consultant Rheumatologists
    • See MHRA Drug Safety Update.
    • See links below.
  • RFL:
    • Approved for Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in line with NICE guidance.
  • RNOH:
    • Restricted for Rheumatology Consultants ONLY.
    • See links below.
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Certolizumab pegol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.01 Cetirizine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • High doses may be used in dermatology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.02.01.01 Cetraben® bath additive 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Dermatology use ONLY
13.02.01 Cetraben® cream 

Cetraben cream, Enopen cream, ExCetra cream, Exmaben cream and Soffen cream all contain Liquid paraffin light 105 mg/g + White soft paraffin 132 mg/g.

Provider notes

  • NMUH:
    • Restricted for prescribing in Paediatrics and by Dermatologists
    • Preferred preparation is Enopen Cream
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Cream 50g, 500g ONLY
13.09 Cetrimide 10% + Undecenoic acid 1% shampoo Ceanel Concentrate®

Provider notes

  • RFL:
    • Dermatology
08.01.05 Cetuximab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Updates
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.01.01 Chloral Hydrate 

Provider notes

  • NMUH:
    • Chloral Mixture, BP 2000, 500mg/5mL (Unlicensed)
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Paediatrics only
    • Chloral hydrate suppositories 25mg & 100mg available
08.01.01 Chlorambucil 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.07 Chloramphenicol 

Provider notes

  • NMUH:
    • Chloramphenicol capsules are non-formulary
    • To be used as per the Trust guidelines for Management of Acute Bacterial Meningitis 
  • RFL:
    • As per agreed indications on microguide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
11.03.01 Chloramphenicol 0.5% eye drops - Single use drops 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.03.01 Chloramphenicol 0.5% eye drops, 1% eye ointment 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Eye drops 0.5% preservative free 10mL (Moorfields special) also available
12.01.01 Chloramphenicol 5% ear drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.01.02 Chlordiazepoxide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to in-patient use for alcohol detoxification and anxiety.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Anxiolytic
    • Alcohol withdrawal
    • Acute phase of mania (off-label)
  • BEHMT approvals:
    • Anxiolytic
    • Alcohol withdrawal
11.03.01 Chlorhexidine 

Provider notes

  • RFL:
    • Chlorhexidine Digluconate 0.02% eye drops (preservative free)
    • Restricted to Opthalmology for use in acanthamoeba keratitis and as an antiseptic in povidone iodine allergy

 

13.11.02 Chlorhexidine + Alcohol wipes Clinell Alcoholic 2% Chlorhexidine Wipes®

Provider notes

  • NMUH:
    • This product is available as individual sachets of 105x105mm in size and comes in boxes of 200.
    • Uses:
      1. Skin antisepsis prior to insertion of peripheral cannulae, or taking blood cultures.
      2. Skin antisepsis prior to taking blood cultures.
      3. Line care: Disinfection of catheter hubs/ports of all IV lines prior to access.
      4. Post insertion line care  (ChloraPrep to be used for skin antisepsis prior to insertion of central line cannulae)
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.11.02 Chlorhexidine 0.015% + Cetrimide 0.15% skin cleaner Tisept®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.02.03 Chlorhexidine 0.1% + Neomycin 0.5% cream Naseptin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Alternative MRSA decolonisation procedure - see microguide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.03.04 Chlorhexidine 0.2% mouthwash 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • MRSA screening procedure
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.03.04 Chlorhexidine 0.2% oral spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to community clinic only
12.03.04 Chlorhexidine 1% dental gel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.04 Chlorhexidine acetate 0.02% catheter maintenance solution 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.11.02 Chlorhexidine skin cleaners 

Provider notes

  • NMUH:
    • The following products are available:
      • ChloraPrep®, Hibiscrub® (see link below for MRSA eradication protocol), Hibitane Obstetric® (restricted to obstetrics), Hydrex®, Unisept®
  • RFL:
    • The following products are avaialble:
      • ChloraPrep®, Hibiscrub®, Hibitane Obstetric®, Hydrex®, Unisept®
  • RNOH:
    • Available products:
      • ChloraPrep®, Hibiscrub®
  • UCLH:
  • WH:
    • Available products:
      • Chlorhexidine 0.05%CX Antiseptic Dusting Powder®, Hibiscrub®, Hibitane Obstetric®, Hydrex®
12.01.03 Chlorobutanol 5% + Arachis (peanut) oil ear drops Cerumol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Chloroprocaine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.04.01 Chloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • To be used as per the NMUHT Malaria Guidelines, see links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Chloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Chlorothiazide 

Provider notes

  • NMUH:
    • For the treatment of chronic hypoglycaemia, heart failure, hypertension and ascites, in children.
    • See the BNF for children for further prescribing information.
    • Chlorothiazide suspension 250mg/5ml, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Chlorothiazide Suspension 250 mg/5 ml (unlicensed product)
03.04.01 Chlorphenamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Tablets, injection and syrup 2mg/5ml available
  • RNOH:
    • Tablets and injection available, Oral syrup available as 2 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
04.02.01 Chlorpromazine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
    • Suppositories are not stocked
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tabs 25 mg, 50 mg, 100 mg. Syrup 25 mg/5ml, 100 mg/5 ml. Injection 50 mg/2ml. Only
04.06 Chlorpromazine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated  
  • RFL:
    • Suppositories are not stocked at RFH
  • RNOH:
    • Oral solution available as 25 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
12.03.01 Choline Salicylate 8.7% oral gel Bonjela® Adult, Teejel®

Provider notes

  • NMUH:
    • Teejel stocked
  • RFL:
    • No restriction stated
  • RNOH:
    • For patients 16 years and above
  • UCLH:
  • WH:
    • No restriction stated
06.05.01 Chorionic Gonadotrophin Choragon®, Pregnyl®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.05.03 Ciclosporin 

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Ciclosporin is restricted to Consultant Gastroenterologists only
    • FBC, LFT & drug level monitoring required
08.02.02 Ciclosporin Deximune®

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Deximune is the first-line choice for all new liver transplant patients. 
    • Previous liver tranplant patients must be maintained on the same brand (usually Neoral).  Brand are not interchangeable.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Ciclosporin Capsorin®

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Ciclosporin Neoral®

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Consultant use only.
  • RFL:
    • Patients must be maintained on the same brand
    • 1st choice for renal transplant
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Ciclosporin Capimune®

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Ciclosporin Sandimmun®

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.03 Ciclosporin 

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Deximune® is the preferred brand
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Ciclosporin 

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Approved for:

  • chronic refractory idiopathic urticaria (JFC - January 2015)
  • severe atopic dermatitis (DMARD fact sheet)
  • severe psoriasis (DMARD fact sheet)

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.99.99.99 Ciclosporin 0.1% eye drops Ikervis®

Approved for ocular inflammatory conditions. See NCL fact sheet. 

 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed Consultant Ophthamologist ONLY
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • For initiation by corneal specialists only
  • WH:
    • Restricted to ophthalmology
11.99.99.99 Ciclosporin 0.2% eye ointment 

Approved for ocular inflammatory conditions. See NCL fact sheet. 

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.03.01 Cimetidine 

 Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Alternative to ranitidine. Tabs 200 mg, 400 mg.
09.05.01.02 Cinacalcet 

Approved for complex primary hyperparathyroidism in adults in line with NHSE clinical commissioning policy (JFC April 2018)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
    • Formulary for treatment of Hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma - see link below
  • RFL:
    • Under Professor Cunningham's recommendation and approved for endocrinology.
  • RNOH:
    • Non-formulary
  • WH:
    • For primary hyperparathyroidism in line with NHSE policy 16034/P
    • For secondary hyperparathyroidism in line with NICE TA 117
04.06 Cinnarizine 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.12 Ciprofibrate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Lipid Clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.12 Ciprofloxacin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • See microguide for agreed indications
    • Microbiology approval required for all other indications
  • RNOH:
    • Oral suspension available as 250 mg/5mL
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
11.03.01 Ciprofloxacin 0.3% eye drops/ointment 

 Provider notes

  • NMUH:
    • Restricted to Ophthalmology department use ONLY.
  • RFL:
    • Restricted to Opthalmology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.05 Cisatracurium 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of cisatracurium is restricted to theatres only.
08.01.05 Cisplatin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.03 Citalopram 

Provider notes

  • NMUH:
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Tablets available. Oral drops available as 40 mg/mL
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Depression
    • 1st/2nd line for Generalized Anxiety Disorder (GAD) (off-label)
    • 1st/2nd line for panic disorder (off-label)
    • 1st/2nd line in social anxiety disorder 
  • BEHMT approvals:
    • Depression
08.01.03 Cladribine injection 

Provider notes

  • NMUH:
    • To be prescribed by the Haematology Team ONLY.
    • Refer to BCSH Guidelines on Hairy Cell Leukaemia
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 Cladribine tablets Mavenclad®

Provider notes

  • RFL:
    • As per NICE TA
05.01.05 Clarithromycin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Microbiologist approval only
    • Oral suspension available as 250 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
05.01.06 Clindamycin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • As per RFL policy on microguide
    • Microbiology approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
13.06.01 Clindamycin 1% topical solution Dalacin T®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
07.02.02 Clindamycin 2% vaginal cream Dalacin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Clobazam 

Provider notes

  • NMUH:
    • Clobazam oral suspension is non-formulary
  • RFL:
    • Blacklist restriction except in epilepsy
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist
13.04 Clobetasol propionate + Neomycin + Nystatin - Topical 

Provider notes

  • RFL:
    • Dermovate NN
    • cream and ointment available
13.04 Clobetasol propionate 0.05% - Topical Dermovate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • cream, ointment and scalp application available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Clobetasol propionate 0.05% shampoo Etrivex®

Provider notes

  • NMUH:
    • For use SECOND LINE in topical treatment of MODERATE SCALP PSORIASIS in adults who have failed treatment with Dermovate 0.05% Scalp Application.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Clobetasol propionate 1 in 4 in White Soft Paraffin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Clobetasol propionate 1 in 4 in White Soft Paraffin 100 g (unlicensed product)
13.04 Clobetasone butyrate 0.05% - Topical Eumovate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Clobetasone butyrate 0.05% + Oxytetracyline 3% + Nystatin - Topical Trimovate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
    • Approved for Pruritus ani; Dermatitis - seborrhoeic - infected; Nappy rash; Infected intertrigo; Eczema - infected
  • WH:
    • No restriction stated
05.01.10 Clofazimine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Microbiology approval only
04.01.01 Clomethiazole 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only capsule is stocked
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.05.01 Clomifene 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

GP-Red Red Hospital only prescribing if used for IVF

GP-Grey Red Other indications

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.01 Clomipramine Antidepressant

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Depression 
  • BEHMT approvals:
    • Depression 
04.02.03 Clonazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT approvals:
    • Anxiety (off-label)
    • Acute phase of mania (off-label)
  • BEHMT approvals:
    • Antimania (off-label)
04.07.03 Clonazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Specialist use only
04.08.01 Clonazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suspension 2 mg/5ml. Suspension should not be administered via PEG tubes as it is incompatible with the polystyrene fittings
02.05.02 Clonidine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Only 25 microgram tablets and the injection kept at the RFH
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.02 Clonidine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
20 Clonidine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
02.09 Clopidogrel 

See NICE TA for eligibility

Provider notes

  • NMUH:
    • To be prescribed as per NICE guidelines - see links below for further details
  • RFL:
    • To be prescribed in line with NICE
    • See NCL summary for information on preferred choices for specific indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.02.02 Clotrimazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Only 1% cream, 200mg Pessaries and 500mg Pessaries stocked
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Pessaries available as 200 mg & 500 mg
13.10.02 Clotrimazole 1% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Cream 1% 20g, solution 1% 20mL and Dusting Poweder 1% 30g available
  • RNOH:
    • Cream 1% only
  • UCLH:
  • WH:
    • Cream 1% 20g, Solution 1% 20mL and Dusting Powder 1% 30g ONLY
12.01.01 Clotrimazole 1% ear drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.02.01 Clozapine Clozaril®

Provider notes

  • NMUH:
    • Restricted to Consultant Psychiatrist use only
    • Monitoring required
    • See links below
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
    • If a patient is admitted on this therapy please ensure that the pharmacy mental health team are aware.
    • Patients being treated in the UK will be registered with CPMS (Clozaril Patient Monitoring Service)
    • See links below
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
21.01 Co‐careldopa 

Rotigotine or co‐careldopa for Hemispatial neglect that is interfering with progress of neurorehabilitation - UCLH only
Approval was subject to Dr Swayne working with Dr Sofat and JFC support to agree the datacollection form and the duration of the pilot study. Duration of audit TBC (November 2016).

13.09 Coal tar 1% + Coconut oil 1% + Salicylic acid 0.5% shampoo Capasal®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to dermatology patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Cocois®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Sebco®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Coal tar and salicylic acid ointment, BP 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.09 Coal tar extract 5% alcoholic shampoo Alphosyl 2 in 1®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Coal tar in Betamethasone ointment 

Provider notes

  • NMUH:
    • To be prescribed by Consultant Dermatologists for the treatment of Psoriasis.
    • Coal Tar 10% in Betamethasone 0.025% Ointment Coal Tar 5% in Betamethasone 0.025% Ointment
    • The above preparations are available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Coal tar lotion 5% Exorex®

Provider notes

  • RFL:
    • Restricted to dermatology
02.02.04 Co-amilofruse  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.02.04 Co-amilozide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
05.01.01.03 Co-Amoxiclav 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 125/31.25 mg/5mL and 250/62.5 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
04.09.01 Co-Beneldopa immediate release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.09.01 Co-Beneldopa modified release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Cobicistat 

Second line protease inhibitor booster for HIV for confirmed ritonavir intolerance (March 2016)

Provider notes

  • NMUH:
    • To be initiated by Consultants in HIV Medicine only
    • See MHRA Drug Safety Updates
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.02.04 Cobimetinib 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.07 Cocaine 10% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Ophthalmology surgery only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.07 Cocaine 4% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is an unlicensed special and restricted to Ophthalmology
    • This is a controlled drug
04.07.02 Cocaine Hydrochloride Solution 10% w/v  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to opthalmology
  • RNOH:
    • Restricted Item Restricted
  • UCLH:
  • WH:
    • Non-formulary
15.02 Cocaine mouthwash 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • 5% mouthwash used for mucositis
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
04.09.01 Co-Careldopa + Entacapone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Co-Careldopa immediate release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.09.01 Co-Careldopa intestinal gel Duodopa®

Approved for Parkinson's disease in line with NHSE clinical commissioning policy D04/P/e (JFC November 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding approval required
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Co-Careldopa modified release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.01 Co-codamol 30/500 Paracetamol + Codeine

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.07.01 Co-codamol 8/500 Paracetamol + Codeine

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.06.02 Co-Cyprindiol 2000/35 (cyproterone 2mg / ethinylestradiol 35micrograms) Dianette®

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.02 Co-danthramer 

Provider notes

  • NMUH:
    • Restricted to terminally ill patients only
  • RFL:
    • Restricted to oncologist and geriatricians
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Because of a potential carcinogenic risk, danthron containing laxatives are indicated only for constipation in the terminally ill. Co-danthramer may cause irritation and excoriation in incontinent patients and may colour the urine red. Please note: Capsules not available. Suspension only.
01.06.02 Co-danthrusate 

Provider notes

  • NMUH:
    • Restricted to terminally ill patients only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary 
  • WH:
    • Non-formulary
01.04.02 Codeine 

NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Codeine 

NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted for patients admitted on codeine, requiring further supply.
    • Oral solution available as 15 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
03.09.01 Codeine Linctus BP 

NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.01 Co-dydramol 10/500 Paracetamol + Dihydrocodeine

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.04 Colchicine 

Provider notes

  • NMUH:
    • See link(s) below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
20 Colchicine  

Approved for oral mucosal inflammatory disease in particular ‘Recurrent apthous stomatitis (RAS)’ and ‘Oral ulceration in Behcet’s disease’ (JFC April 2018).

Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC, U&E and LFTs at 3 months, 6 months and then annually, CK only if myalgia.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
09.06.04 Colecalciferol + Calcium carbonate Adcal-D3®

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.06.04 Colecalciferol caps/liquid 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral liquid available as 3000 units/mL
  • UCLH:
  • WH:
    • No restriction stated
02.12 Colesevelam Cholestagel®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary for hypercholesterolaemia 
    • Available for partial biliary obstruction, primary biliary cirrhosis and diarrhoea if colestyramine and colestipol is unavailable (off-label)
    • Cholestagel should be administered at least 4 hours before or at least 4 hours after the concomitant medication in order to minimize the risk of reduced absorption of the concomitant medication
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
02.12 Colestipol Colestid®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Lipid clinic for hypercholesterolaemia 
    • Restricted to Hepatology / Gastroenterology for partial biliary obstruction, primary biliary cirrhosis and diarrhoea if colestyramine is unavailable (off-label)
    • Patients should take other drugs at least 1 hour before or 4 hours after colestipol to minimise possible interference with their absorption
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.09.02 Colestyramine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Questran Light preferred owing to lower sugar content
    • Current shortage - colestipol is the recommended alternative
    • As a precautionary measure, where concurrent drug therapy exists then such drugs should be administered at least one hour before or 4-6 hours after colestyramine.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.12 Colestyramine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Questran Light preferred owing to lower sugar content
    • Restricted to Lipid Clinid for hypercholesterolaemia 
    • Current shortage - colestipol is the recommended alternative
    • As a precautionary measure, where concurrent drug therapy exists then such drugs should be administered at least one hour before or 4-6 hours after colestyramine.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.07 Colistimethate for nebulisation 

Provider notes

  • NMUH:
    • Microbiology recommendation only
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Check with Microbiology
05.01.07 Colistimethate injection 

Provider notes

  • NMUH:
    • Microbiology recommendation only
  • RFL:
    • Consultant Microbiology/ID approval only
  •  RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Check with Microbiology
13.10.05 Collodion Flexible BP 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.01.01 Co-magaldrox 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only Mucogel kept
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suspension (Maalox) containing magnesium hydroxide 195mg, dried aluminium hydroxide 220mg/5ml. Na+ content 0.24mmol/5ml
09.02.02.01 Compound Sodium Lactate (Hartmann's) Intravenous Infusion 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • 500 mL and 1000 mL
  • UCLH:
  • WH:
    • No restriction stated
03.04.03 Conestat Alfa 

Approved for prophylaxis and treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC October 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For hereditary angioedema in line with NHSE comissioning policy
    • Restricted to immunology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

 

06.04.01.01 Conjugated oestrogen Premarin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 300 microgram tablets are not stocked
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Conjugated oestrogen with Medroxyprogesterone Premique®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tabs containing conjugated oestrogens 625 micrograms and medroxyprogesterone acetate 5 mg ONLY
01.04.02 Co-Phenotrope 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.04 Co-tenidone (atenolol and chlortalidone)  

Provider notes

  • RFL:
    • No restriction stated
05.01.08 Co-trimoxazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to treatment and prevention of PCP infection; Chemotherapy protocols
    • Microbiology approval required for all other indications
  • RNOH:
    • Oral suspension available as 40/200 mg/5mL and 80/400 mg/5mL
  • UCLH:
  • WH:
    • Microbiology approval only
A2.03.01 Cow and Gate Pepti-Junior 

Provider notes

  • NMUH:
    • Suitable for infants from birth for:
      • protracted diarrhoea
      • food intolerance
      • short bowel
      • cystic fibrosis
      • inflammatory bowel disease
      • malnutrition
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Crisantaspase 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Crizotinib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA drug safety alerts
    • See London Cancer Guidelines for the Treatment of Lung Cancer
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additonally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.03 Crotamiton 10% cream Eurax®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
09.01.02 Cyanocobalamin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.06 Cyclizine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
    • Tablets approved for:
      • Nausea
      • Vomiting
      • Labyrinthine disorders
      • Motion sickness
      • Vertigo
      • Prevention/treatment of post-operative nausea and vomiting
      • Nausea or vomiting associated with radiotherapy
      • Nausea and vomiting associated with narcotic analgesics
    • Injection approved for:
      • Nausea
      • Vomiting
      • Labyrinthine disorders
      • Motion sickness
      • Vertigo
      • Prevention/treatment of post-operative nausea and vomiting
      • Pre-op. emergency surgery: Reduce regurgitation/aspiration gastric contents
      • Nausea or vomiting associated with radiotherapy
      • Nausea and vomiting associated with narcotic analgesics
  • WH:
    • No restriction stated
11.05 Cyclopentolate eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
11.05 Cyclopentolate eye drops - single use 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.01 Cyclophosphamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
    • For immune system disorders refer to local protocols
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Cyclophosphamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • RFL
    • Approved for use in Scleroderma (lung fibrosis), Vasculitis, SLE and Sarcoid
    • For patients receiving  high doses of cyclophosphamide will also require supporting and preventative  therapy with co-trimoxazole 480mg OD, Calcichew D3 forte 2 OD, nystatin suspension 1ml QDS, lansoprazole 30mg OD or omeprazole 20mg OD or ranitidine 150mg BD will be prescribed.
05.01.09 Cycloserine 

Provider notes

  • NMUH:
    • Restricted for the use in combination with other drugs for Tuberculosis resistant to first line drugs only
  • RFL:
    • Microbiology/ ID approval only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted to TB clinic or as per Microbiology advice
03.04.01 Cyproheptadine 

Provider notes

  • NMUH:
    • Stocked in the Emergency Drug Cupboard ONLY as an antidote for serotonin syndrome.
  • RFL:
    • No restriction stated
    • Dermatology use in the treatment of cold urticaria
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Cyproterone 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.02 Cyproterone Acetate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • In view of hepatotoxicity associated with long-term daily doses of 300 mg daily, the CSM recommend the use of cyproterone in prostatic cancer should be restricted to:
      • Short courses to cover testosterone flare associated with LHRH agonists.
      • Treatment of hot flushes after orchidectomy or LHRH agonists.
      • Patients who do not respond to, or are intolerant of other treatments.
    • Tabs 50 mg, 100 mg
08.01.03 Cytarabine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.08.02 Dabigatran 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted for thromboprophylaxis post elective total hip or knee replacement surgery and emergency hip fracture surgery, as per Trust guidelines.
    • See links below
    • Check MHRA Drug Safety Updates
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and faxed to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL:
    • As per NICE guidance
    • Follow NCL DOAC prescribing guide
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for use as thromboprophylaxis after elective hip and knee surgery
08.01.05 Dabrafenib caps 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Dacarbazine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.03.03.02 Daclatasvir  

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 Daclizumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.02 Dactinomycin 

Not approved for Relapsed/refractory acute myeloid leukaemia (AML) (JFC October 2016)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.07 Dalbavancin infusion 

Approved if recommended by Microbiology for skin and soft tissue infections in patients only if (JFC April 2017):

  • unable to receive oral therapy and
  • available treatment pathways for repeated IV antibiotics are unsuitable e.g. chaotic lifestyle, immobility, poor venous access

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Microbiology Consultant only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Skin and soft tissue infections in patients unable to receive oral therapy- Restricted to Microbiology recommendation (JFC April 2017)
  • WH:
    • As above (restricted to Microbiology)
02.08.01 Danaparoid 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per local protocol only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Danazol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.02.02 Dantrolene sodium 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.01.08 Dantrolene sodium injection 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • Stock kept in theatres on Malignant Hyperthermia trolley
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Dantrolene Injection is kept in the following locations: Main Theatres, Obstetrics Theatre
06.01.02.03 Dapagliflozin 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Restricted to Endocrinology
  • RNOH:
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH:
  • WH:
    • No restriction stated
05.01.10 Dapsone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
20 Dapsone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for oral mucosal inflammatory conditions: mucous membrane pemphigoid (MMP), recurrent aphthous stomatitis (RAS) and linear IgA bullous dermatosis (JFC April 2018)

Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC and reticulocyte count weekly for four weeks, monthly for 6 months, then every 3 months thereafter. LFTs should be monitored monthly for 3 months, then every 3 months thereafter for duration of therapy.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
05.01.07 Daptomycin 

Store in a refrigerator

Provider notes

  • NMUH:
    • Consultant Microbiologist approval only
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
08.02.04 Daratumumab injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
09.01.03 Darbepoetin alfa Aranesp®

Provider notes

  • NMUH:
    • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
  • RFL:
    • Restricted to renal team only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 323
05.03.01 Darunavir 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Darunavir + Cobicistat Rezolsta®

Provider notes

  • NMUH:
    • To be initiated by Consultants in HIV Medicine only
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide Symtuza®

Approved for HIV infection in line with NHSE commissioning policy F03/P/b (JFC January 2019)

 Provider notes

  • NMUH:
    • To be prescribed by the HIV team only, as per the clinical commissioning policy - see link below.
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.03.02 Dasabuvir 

Provider notes

  • NMUH:
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • For use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Dasatinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patient this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.02 Daunorubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.02 Daunorubicin liposomal DaunoXome®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.03 Deferasirox 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Prior funding approval required
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.02 Deferasirox (free of charge)  

Deferasirox film-coated tablets (post-trial access) for transfusion related iron-overload in transfusion dependant thalassaemia and sickle cell disease (or non-transfusion dependant iron overload in patients with thalassaemia intermedia) (JFC November 2016)

09.01.03 Deferiprone 

Provider notes

  • NMUH:
    •  To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tabs 500 mg ONLY
06.03.02 Deflazacort 

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Rheumatology and Endocrinology only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Degarelix 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.09 Delamanid 

Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NHSE policy for XDR-TB and MDR-TB
  • RNOH:
    • Non-formulary  
  • UCLH:
    • Pulmonary multidrug-resistant tuberculosis in line with NHS England policy, restricted to TB team
  • WH:
    • TB clinic only
05.01.03 Demeclocycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • ???
  • WH:
    • Microbiology approval only
06.05.02 Demeclocycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • For treatment of SIADH
  • RFL:
    • For treatment of SIADH
  • RNOH:
    • Treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable. Initially 0.9–1.2 g is given daily in divided doses, reduced to 600–900 mg daily for maintenance.
  • UCLH:
  • WH:
    • ???
06.06.02 Denosumab XGEVA®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for preventing skeletal related events for oncology patients subject to service redevelopment (November 2015)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by the Oncology team ONLY.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Giant cell tumour of bone
  • UCLH:
  • WH:
    • No restriction stated
06.06.02 Denosumab Prolia®

Approved for osteoporosis in women (see NICE TA) and men unable to take oral bisphosphonates (either due to intolerance or unable to comply with administration instructions) and unable to receive IV zoledronic acid due to renal dysfunction (JFC October 2017)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Rheumatology and Care of the Elderly Consultants ONLY.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • Approved for osteoporosis treatment by Endocrinology, Rheumatology
  • RNOH:
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Also approved for osteoporosis in men unable to take oral biphosphonates and unable to receive IV zoledronic acid due to renal dysfunction (November 2017)
20 Denosumab XGEVA®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for hypercalcaemia of malignancy who are either refractory to bisphosphonates or have creatinine clearance <30mL/min in whom bisphosphonates are contraindicated (JFC August 2018).

Only on the advice of oncology or palliative care consultants.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per above agreed indication
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
07.02.02 Dequalinium chloride vaginal tablets 

Approved for bacterial vaginosis as a second-line alternative to clindamycin 2% intravaginal cream in patients who have not tolerated or failed metronidazole treatment (JFC August 2018).

Provider notes

  • NMUH:
    • Restricted to GU medicine ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
13.02.01 Dermamist® spray application 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    •  Restricted to Paediatric Dermatology outpatients.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

 

13.02.02 Derma-S® barrier preparation 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
13.02.01 Dermatonics Once Heel Balm® Urea 25%

JFC approved for primary and secondary care for treatment of anhidrotic, fissured, calloused and hard foot skin in diabetic patients at high risk of ulceration (March 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See indication above.
    • Restricted to podiatry use ONLY
13.02.01 Dermol® 500 lotion 

Provider notes

  • NMUH:
    • Restricted to the Dermatology team
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Dermol® bath/shower additive 

Provider notes

  • RFL:
    • Dermol 200 shower gel and 600 bath emollient available
13.02.01 Dermol® cream 

Provider notes

  • RFL:
    • No restriction stated
09.01.03 Desferrioxamine Mesilate 

Provider notes

  • NMUH:
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • Prior funding approval required for desferrioxamine infusors.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
18 Desferrioxamine Mesilate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.02 Desflurane 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.04.01 Desloratadine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of desloratadine is reserved for consultant ENT surgeons only
    • Tabs 5mg ONLY
06.05.02 Desmopressin 

Provider notes

  • NMUH:
    • DDAVP: On formulary
    • DesmoMelt: Formulary for use as a first line agent in the treatment of primary nocturnal enuresis
  • RFL:
    • DDAVP: Restricted to child health; sublingual tablets available (120micrograms and 240micrograms)
    • Desmotabs: Restricted to child health
    • Desmospray: On formulary
    • Octim: On formulary
    • Injection: 4micrograms in 1mL available
  • RNOH:
    • Tablets, Injection, Nasal spray (for continuation of treatment), Oral lyophilisates (for continuation of treatment)
  • UCLH:
  • WH:
    • DDAVP: Intranasal solution 100 micrograms/1 ml & Inj 4 micrograms/1 ml ONLY
    • DesmoMelt: The use of Desmomelt tablets is restricted to Paediatrics only
    • Desmotabs: The use of desmopressin tablets is restricted to Dr Rossi only
    • Desmospray: On Formulary
07.03.02.01 Desogestrel 75mcg pill generic, Cerazette®, Cerelle®, other brands available

Provider notes

  • NMUH:
    • Preferred brand = generic
    • Restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Approved for Sexual Health and Family Planning (Marlborough Clinic). Also approved for Obs and Gyn.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.02.02 Dexamethasone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • No restriction stated
11.04.01 Dexamethasone + Framycetin + Gramicidin drops Sofradex®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.01.01 Dexamethasone + Framycetin + Gramicidin drops Sofradex®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
12.01.01 Dexamethasone + Neomycin + Glacial Acetic Acid ear spray  Otomize®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to ENT department use only
11.04.01 Dexamethasone + Neomycin + Polymyxin B drops, ointment Maxitrol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.01.01 Dexamethasone 0.1% + Ciprofloxacin 0.3% ear drops Cilodex®

Approved for treatment of acute otitis externa with perforated/damaged tympanic membrane (JFC March 2018)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
11.04.01 Dexamethasone 0.1% eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.04.01 Dexamethasone 0.1% eye drops - preservative free 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Dexamethasone eye drops 0.1% preservative-free (Moorfields)
11.04.01 Dexamethasone intravitreal implant Ozurdex®

 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.03.02 Dexamethasone oral and systemic injection 

Provider notes

  • NMUH:
    • See MHRA Drugs Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • The use of dexamethasone inj 24mg/ml is restricted to theatres only
04.04 Dexamfetamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary  
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As per NICE TA98 / CG87
15.01.04.04 Dexmedetomidine injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for light sedation (RASS 0 to -3) in mechanically ventilated adult patients with CAM ICU positive agitated delirium where agitation precludes weaning and extubation only after standard sedative agents (including propofol, clonidine or a benzodiazepine) had been trialled for 48 hours. (JFC January 2019).

Provider notes

  • NMUH:
  • RFL:
    • see above indication
    • Refer to local protocol for use
  • RNOH:
  • UCLH:
  • WH:
    • As above.
04.07.02 Diamorphine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.01.02 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • Tablets 2 mg, 5 mg, 10 mg.
    • Oral solution 2 mg/5 ml, 5mg/5 ml 
    • Injection (emulsion) 10 mg/2 ml - Diazemuls
  • CIFT approvals:
    • Anxiolytic
    • Alcohol withdrawal
    • Acute phase of mania (off-label)
  • BEHMT approvals:
    • Anxiolytic
    • Alcohol withdrawal
    • Acute phase of mania (off-label)
04.08.02 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Only diazepam injection (emulsion) and rectal solution stocked
  • RNOH:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • ‘Diazemuls’ are preferred to plain diazepam injection as they are less likely to cause thrombophlebitis
10.02.02 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
15.01.04.01 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.04 Diazoxide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to children < 1year
20 Dibotermin Alfa, rhBMP-2 Inductos®

 Provider notes

  • RNOH:
    • Complex spinal funsion surgeries in line with NHSE commissioning policy
    • Restricted Item Restricted This product is currently unavailable in the UK
13.08.01 Diclofenac 3% gel Solaraze®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatologists
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.01 Diclofenac Sodium  

Provider notes

  • NMUH:
    • See MHRA Drug Safety Update
  • RFL:
    • Restricted to Rheumatology and Obstetricians / Gynaecology
    • Injection, Suppositories 12.5mg/25mg/100mg, EC tablets 25mg/50mg 
  • RNOH:
    • Restricted: Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking).
  • UCLH:
  • WH:
    • See MHRA Drug Safety Update
10.01.01 Diclofenac sodium + Misoprostol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Must not be given to women of child-bearing potential
11.08.02 Diclofenac Sodium 0.1% eye drops - single use Voltarol® Ophtha

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Diclofenac sodium Modified release 

Provider notes

  • NMUH:
    • Non-formulary
    • Check MHRA Drug Safety Updates 
  • RFL:
    • Restricted to only Rheumatology and Obs / Gynae
    • M/R tablets 75mg and 100mg available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See MHRA Drug Safety Update
18 Dicobalt edetate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.02 Dicycloverine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Didanosine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.03.01 Diethylstilbestrol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Diflucortolone valerat 0.3% - Topical Nerisone Forte®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Oily cream and ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Oily Cream ONLY
13.04 Diflucortolone valerate 0.1% - Topical Nerisone®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Cream, oily cream and ointment are available 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.01.01 Digoxin 

Provider notes

  • NMUH:
    • NB. The Digoxin 100 micrograms/mL (Paediatric) is unlicensed and NON-FORMULARY. 
  • RFL:
    • No restriction stated
  • RNOH:
    • Tablets available. Oral elixir available as 50 micrograms/mL
  • UCLH:
  • WH:
    • No restriction stated
02.01.01 Digoxin specific antibody fragments Digifab®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Dihydrocodeine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral elixir available as 10 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Dihydrocodeine modified release  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
21.01 Diltiazem cream 

Diltiazem cream for transrectal ultrasound guided prostate biopsy
Twelve-month evaluation at UCLH site only (March 2015)

01.07.04 Diltiazem Cream 2% 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.06.02 Diltiazem immediate release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.06.02 Diltiazem modified release 

Prescribe by brand name: modified-release preparations have different release characteristics and are not interchangeable.

Provider notes

  • NMUH:
    • Adizem-SR, Adizem-XL, Tildiem LA, Tildiem Retard available
  • RFL:
    • Tildiem LA, Tildiem Retard and Slozem and the preferred brands
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Tildiem LA, Tildiem Retard available
08.02.04 Dimethyl fumarate Tecfidera®

DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Dimethyl fumarate Skilarence®

DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.01.01 Dinoprostone Prostin E2®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only Intravenous solution and Vaginal Gel are kept at the Royal Free Hospital
    • See link below
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Vaginal gel 1 mg/2.5 ml (Prostin E2), Vaginal gel 2 mg/2.5 ml (Prostin E2) Inj 5 mg/0.5 ml extra amniotic
07.01.01 Dinoprostone Propess®

Provider notes

  • NMUH:
    • Restricted to Obstetrics and Gynaecology Consultants only for induction and Augmentation of Labour
  • RFL:
    • See link below
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.04 Diphtheria antitoxin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Unlicensed product
13.02.01 Diprobase® cream 

Provider notes

  • NMUH:
    • Restricted to Dermatology team
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • 50g, 500g only
02.09 Dipyridamole 

See NICE TA for eligibility

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • See NCL JFC summary of antiplatelet options in cardiovascular disease for advice on specific indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.03.02 Disopyramide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.03.02 Disopyramide modified release Rythmodan® Retard

Provider notes

  • RFL:
    • For cardiology only
04.10.01 Disulfiram 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Dithranol cream Dithrocream®

Provider notes

  • NMUH:
    • Dithrocream 0.25% and Dithrocream 0.5% are FORMULARY, for irritation on trunk and limbs.
    • Dithrocream 0.1%, Dithrocream 1% and Dithrocream 2% are NON-FORMULARY.
  • RFL:
    • Dithrocream 0.1%, 0.25%, 0.5%, 1% and 2% available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Dithranol Paste, BP 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.07.01 Dobutamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Docetaxel 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • No restrictions stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Breast and lung cancer
08.01.05 Docetaxel + oxaliplatin + disodium folinate + fluorouracil (FLOT) 

Approved gastric or gastro-oesophageal junction adenocarcinoma (JFC November 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
    • As above
  • WH:
    • Non-formulary
01.06.02 Docusate sodium 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Caps 100mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
  • UCLH:
  • WH:
    • Caps 100 mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
05.03.01 Dolutegravir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Dolutegravir + Abacavir + Lamivudine Triumeq®

Approved for HIV in line with NHSE Commissioning Policy B06/P/a.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.02 Domperidone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See MHRA safety alert
  • RNOH:
    • Tablets availabe. Oral suspension available as 1 mg/mL.
  • UCLH:
    • Non-formulary
  • WH:
    • See MHRA safety alert
04.06 Domperidone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Check MHRA Safety Drug Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 1 mg/mL 
  • UCLH:
  • WH:
    • Risk of cardiac side effects - to be used at the lowest effective dose for the shortest period of time
04.11 Donepezil 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Care of the Elderly consultants only
    • Tabs 5mg only
02.07.01 Dopamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.07.01 Dopexamine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only available for liver transplant patients and continuation of treatment.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Dorzolamide 2% + Timolol 0.5% eye drops Cosopt®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.06 Dorzolamide 2% + Timolol 0.5% eye drops - unit dose Cosopt®

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
  • UCLH:
  • WH:
    • Restricted to Ophthalmology 
11.06 Dorzolamide 2% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Not to be used as first-line treatment - see link below
11.06 Dorzolamide 2% eye drops - unit dose 

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.03.01 Dosulepin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.02 Dosulepin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.02.01 Doublebase® gel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
03.05.01 Doxapram 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.01.07 Doxapram 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
02.05.04 Doxazosin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Immediate release preparations only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Immediate release preparations only.
    • Prolonged release preparations not recommended for routine use by NHSE (Dec 2017)
07.04.01 Doxazosin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Modified release preparations are non-formulary
  • RFL:
    • Modified release preparations are non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Modified release praparations are non-formulary
08.01.02 Doxorubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Inj 50 mg ONLY
08.01.02 Doxorubicin pegylated liposomal Caelyx®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.03 Doxycycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Oral: No restriction stated
    • IV: Seek Microbiology, ID or Pharmacy advice before prescribing
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.04.01 Doxycycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.03.02 Dronedarone 

Provider notes

  • NMUH:
    • NOT 1ST LINE DRUG - REQUIRES CARDIOLOGIST APPROVAL.
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • No restriction stated
  • RNOH:
    • Requires CARDIOLOGIST approval
  • UCLH:
  • WH:
    • For use in the treatment of Non‐Permanent Atrial Fibrillation (AF) where it is not the first‐line option; this is use is limited to an SpR or a Consultant cardiologist who has seen the patient.
06.01.02.03 Dulaglutide 

Semaglutide is the preferred GLP-1 receptor agonist for type 2 diabetes, when used in line with the NCL Fact sheet (JFC August 2019).

Dulaglutide should only be initiated for patients (JFC August 2019):

  • who are needle-phobic and cannot use the semaglutide pen device.
  • with impaired manual dexterity (e.g. due to severe arthritis) and cannot use the semaglutide pen device.
  • with learning difficulty or mental health issues and require GLP-1 receptor agonist administration by a third-party as the dulaglutide device minimises the risk of needle-stick injury

 

Provider notes

  • NMUH:
    • Non-formulary but see link below
  • RFL:
    • Restricted to Endocrinology only
  • RNOH:
    • Requires initiation by a Diabetes Specialist
  • UCLH:
  • WH:
    • As above
04.03.04 Duloxetine Cymbalta®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
04.07.03 Duloxetine Cymbalta®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Restricted for patients who cannot tolerate, or have an inadequate response to, gabapentin.

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, gabapentin.
    • See link below
  • UCLH:
  • WH:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, gabapentin
    • See link below
07.04.02 Duloxetine Yentreve®

DO NOT CONFUSE CYMBALATA® AND YENTREVE® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Provider notes

  • NMUH:
    • Duloxetine (Yentreve) is FORMULARY for use in women with moderate to severe urinary stress incontinence. Duloxetine (Yentreve) should be used as a second line option for urinary stress incontinence, as an alternative to surgical treatment, as per NICE guidance.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.02.04 DuoDERM Extra Thin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.01 Dupilumab injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For the treatment of Atopic Dermatitis in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.01.02 Durafiber 

Absorbent Cellulose dressing with gel matrix 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.03.03 Durafiber Ag 

Provider notes

  • NMUH:
    • To be used on the recommendation of the Tissue Viability Nurse only.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Durvalumab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Dutasteride 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use by Dermatology for frontal fibrosing alopecia (third line drug. Off label use)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 E45® cream 

Provider notes

  • NMUH:
    • E45 cream is NON-FORMULARY.
    • Cetomacrogel A cream (500g) is used at NMUHT.
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary

 

A5.02.03 Eclypse Adherent 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.02.02 Econazole Gyno-Pevaryl®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only Gyno-Pevaryl 'Single dose' Pessary stocked
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.03.02 Econazole 1% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is an unlicensed special and restricted to Ophthalmology
09.01.03 Eculizumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE
  • RNOH:
    • Non-formulary
  • UCLH:
    • See links below
  • WH:
    • Non-formulary
20 Eculizumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for 2nd line management of Delayed Haemolytic Transfusion Reactions [DHTRs] hyperhaemolysis in adult Sickle Cell and β-thalassaemia patients who have not responded to IVIG and steroids (pending internal funding approval; JFC July 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Restricted to haematology. UMC to be informed of each patient. Funding agreed for 1 patient per annum. 
  • WH:
    • Non-formulary
21.02 Eculizumab (free of charge)  

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for Cold Agglutinin Disease (July 2016, October 2016)

Provider notes

  • RFL:
    • No restriction stated
  • UCLH approvals:
    • Waldenstrom's macroglobulinaemia. For CAD under Dr D'Sa's clinic as last line option - UMC June 2016
02.08.02 Edoxaban 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

  • NMUH:
    • Positive NICE TA - This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL:
    • As per NICE guidance
    • Follow NCL DOAC prescribing guide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Not to be used for initiation of therapy.
05.03.01 Efavirenz 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • As per HIV guidelines
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.09 Eflornithine 11.5% cream Vaniqa®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to dermatology and endocrinology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.03.02 Elbasvir + Grazoprevir 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A2.01.01.02 Elemental 028 ® Extra 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Eliglustat 

Approved for type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive metabolisers (JFC November 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For Gaucher disease in line with NICE
  • RNOH:
    • Non-formulary
  • UCLH:
    • Gaucher disease in line with NICE HST
  • WH:
    • Non-formulary
09.01.04 Eltrombopag 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines see link below.
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
01.04.02 Eluxadoline 

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • NICE TA471 applies
02.11 Emicizumab 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for congenital haemophilia A with factor VIII inhibitors in line with NHSE clinical commissioning policy 170067/P (RFL only; JFC November 2018)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Empagliflozin 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Restricted to Endocrinology
  • RNOH:
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Emtricitabine 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
    • Patients currently benefiting from FTC in their combination therapy, who either accessed FTC in studies or move to London with FTC as part of their existing regimen, should continue to receive FTC without interruption
    • For patients who have previously not received 3TC, the decision to prescribe 3TC or FTC to be made by the clinician and patient after discussion and consideration of relevant factors
  • RFL:
    • As per HIV guidelines
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Emtricitabine + Rilpivirine + Tenofovir disoproxil Eviplera®

Provider notes

  • NMUH:
    • NHSE approval required
    • Initiation restricted to Consultants HIV Medicine
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Emtricitabine + Tenofovir alafenamide Descovy®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Emulsiderm® liquid emulsion 

Provider notes

  • NMUH:
    • Restricted to Dermatology team
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Emulsifying Ointment, BP 

Provider notes

  • NMUH:
    • Stock 500g tub
    • Emulsifying ointment can be used as a soap substitute
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.05.05.01 Enalapril  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Encorafenib caps 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Enfuvirtide 

Provider notes

  • NMUH:
    • To be used in accordance with the London HIV consortium BHIVA guidelines
    • For HIV team only
    • Patients currently benefiting from enfuvirtide in their combination therapy should continue to receive enfuvirtide without interruption. Current benefit is defined as patients whose viral load is either undetectable or remaining below their pre-enfuvirtide baseline level. Patients whose current viral load has substantially rebounded or returned to their baseline level when their first used enfuvirtide and who have a strong CD4 count, are likely to have developed or be developing resistance to enfuvirtide. Enfuvirtide is also unlikely to be having antiretroviral activity, and these patients should consider stopping the enfuvirtide in their combination, with close monitoring BHIVA Guidelines - Treatment of HIV-1 infected adults with antiretroviral therapy
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
14.04 Engerix B® Hepatitis B vaccine Single Component

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.08.01 Enoxaparin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prophylaxis - only whilst tinzaparin shortage
    • Treatment - haemophilia recommendation only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.01.02 Enoximone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.04.01.02 Enshake 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.03 Ensure Compact 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.01 Ensure Plus Advance 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.01 Ensure Plus Fibre 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.01.02 Ensure Plus Juce 

Provider notes

  • NMUH:
    • Taste aberrations/aversions to milky supplements, fat intolerance/streatorrhoea, Cancer cachexia, poor wound healing, anorexia, Disease related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished. Proven inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagia Non-milk tasting. For patients who dislike milk. Used to meet nutritional requirements in addition to oral intake
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.01 Ensure Plus Milkshake style 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.01 Ensure Plus Yoghurt style 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.03 Ensure Twocal 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Entacapone 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see link)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
    • Parkinson's disease - adjunct to levodopa + dopa-decarboxylase inhibitor
  • WH:
    • Entacapone is available for use by Care of the Elderly and Neurology Consultants only
05.03.03.01 Entecavir 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • Restricted to Hepatology in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.03.04.02 Enzalutamide 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
14.04 Enzira® Influenza vaccine

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Epaderm® cream/ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

 

02.07.02 Ephedrine 

Provider notes

  • NMUH:
    • Restricted for use in Theatres only.
  • RFL:
    • None
  • RNOH:
    • In idiopathic orthostatic hypotension in spinally injured patients
  • UCLH:
  • WH:
    • Ephedrine inj is available for use by anaesthetists only.
12.02.02 Ephedrine 0.5% nasal drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
20 Ephedrine tablets 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Approved for use for priaspism (unlicensed use).
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.02 Epirubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.02.03 Eplerenone 

Approved for heart failure in patients unable to tolerate spironolactone due to gynacomastia (JFC April 2017)

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
    • Restricted for patients who are unable to tolerate spironolactone due to gynaecomastia
  • RFL:
    • Restricted to Cardiology
  • RNOH:
    • Requires CARDIOLOGIST approval
  • UCLH:
    • Restricted to patients intolerant of spironolactone due to gynacomastia
  • WH:
    • Eplerenone is reserved for the use of Consultant Cardiologists only for those who develop gynaecomastia with spironolactone
09.01.03 Epoetin alfa Eprex®

Provider notes

  • NMUH:
    • For anaemia associated with chronic renal failure only.
    • Restricted to renal consultants signature and Dr. Tindall signature only.
    • Please note that the CSM has advised that the subcutaneous route is contraindicated in chronic renal failure. Please use the IV route instead. The dialysis unit has changed over to NeoRecormon which is an IV preparation.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Epoetin is available for treatment anaemia of renal disease only
09.01.03 Epoetin beta NeoRecormon®

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Renal and Haematology Consultants.
    • See MHRA drug safety updates 
  • RFL:
    • Renal anaemia
  • RNOH:
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Epoetin is available for treatment anaemia of renal disease only
    • Pre-filled syringe 2,000 units, 3,000 units, 4,000 units, 6,000 units, 10,000 units ONLY
02.08.01 Epoprostenol 

Approved for pulmonary hypertension (November 2013)

Provider notes

  • NMUH:
    • Restricted for ICU use only.
    • Check MHRA for Drug Safety Updates
  • RFL:
    • Restricted to ITU and pulmonary hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for primary pulmonary hypertension: functional grades III + IV
    • Approved for Inhibition of platelet aggregation during renal dialysis
  • WH approvals:
    • No restriction stated
02.09 Eptifibatide Integrilin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.06.04 Ergocalciferol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Inj 7.5 mg (300,000 units)/1 ml only
07.01.01 Ergometrine Maleate 

Provider notes

  • NMUH:
    • Restricted to Obstetrics Only 
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.01.01 Ergometrine Maleate + Oxytocin Syntometrine®

Provider notes

  • NMUH:
    • Restricted to Obstetrics ONLY
  • RFL:
    • See Maternity Unit Guideline on Massive Obstetric Haemorrhage
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.01 Ergotamine Tartrate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Eribulin 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Erlotinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when use in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology team ONLY.
    • See links below
  • RFL:
    • AS per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.02.02 Ertapenem 

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Microbiology approval only (except ITU, microbiology approval required within 48 hours)
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Restricted antibiotic - Microbiology approval only
06.01.02.03 Ertugliflozin tabs 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
01.02 Erythromycin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL: 
    • Off-label use
  • RNOH: 
    • Off-label use
  • UCLH:
  • WH:
    • Off-label use
05.01.05 Erythromycin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Injection is reserved for the use of Paediatrics only
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 125 mg/5mL and 250 mg/5mL
  • UCLH:
  • WH:
    • Restricted to Maternity use or as prokinetic
11.03.01 Erythromycin 0.5% eye ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is unlicensed special and restricted to Ophthalmology
13.06.01 Erythromycin 40mg + Zinc acetate 12mg/mL topical solution Zineryt®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.03 Escitalopram 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT approvals:
    • Social anxiety disorder and if other SSRIs are not appropriate
    • Depression
  • BEHMT approvals:
    • Non-formulary
02.04 Esmolol 

Provider notes

  • NMUH:
    • Only 100mg/10ml vials are kept at NMUHT.
  • RFL:
    • Restricted to ITU, cardiology and theatres only.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.03.05 Esomeprazole 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • RFH: Non-formulary
    • BCF: No restriction stated (historical use)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
06.04.01.01 Estradiol Zumenon®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol Elleste-Solo®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.02.01 Estradiol 10mcg vaginal tablet Vagifem®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.02.01 Estradiol 7.5mcg /24hrs 7.5 microgram/24 hours vaginal delivery system Estring®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol gel Oestrogel®

Approved as hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women (JFC September 2018).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the menopause clinic only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
06.04.01.01 Estradiol patch Evorel®, FemSeven®, Estradot®, Estraderm MX®, Progynova TS®

Provider notes

  • NMUH:
    • FemSeven available
  • RFL:
    • Evorel 25micrograms/hr, 50micrograms/hr and 100micrograms/hr available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Evorel 50 micrograms/24 hours,100 micrograms/24 hours ONLY. For patients requiring 25 micrograms of estradiol per day, the Evorel 50 micrograms patch may be cut in half.
06.04.01.01 Estradiol with Dydrogesterone Femoston

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Femoston 1/10, 2/10 and Femoston-Conti 1/5 available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Femoston-conti tablets & Femoston 1/10 tablets ONLY
06.04.01.01 Estradiol with Levonorgestrel patch FemSeven® Conti

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Levonorgestrel patch FemSeven® Sequi

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Norethisterone Climesse®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol with Norethisterone Elleste-Duet Conti®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • ???No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Norethisterone Elleste-Duet®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Norethisterone Kliofem®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Norethisterone Kliovance®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol with Norethisterone patch Evorel® Conti

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol with Norethisterone patch Evorel® Sequi

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.02.01 Estriol 0.01% vaginal cream Gynest®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.02.01 Estriol 1mg/1g vaginal cream Ovestin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Etanercept 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

JFC approved Benepali as the brand of choice.

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TAs below)
  • Ankylosing spondylitis (see NICE TAs below)
  • Psoriatic Arthritis (PsA; see NICE TAs below)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Restricted to Consultant Rheumatologists
    • See MHRA Drug Safety Update
    • See links below
  • RFL:
    • Approved for use in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in line with NICE guidance
  • RNOH:
    • Rheumatology Consultants ONLY
    • Please prescribe by brand name Benepali or Enbrel - patients requiring 50 mg should be prescribed Benepali and patients requiring 25 mg should be prescribed Enbrel
    • See links below
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Etanercept 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

JFC approved Benepali as the brand of choice.

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Dermatologists
    • Check MHRA safety updates.
    • See links below.
  • RFL:
    • Approved for use in the treatment of Psoriasis in line with NICE guidance
    • Homecare available - usually after first month
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
20 Etanercept 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

JFC approved Benepali as the brand of choice.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to National Amyloidosis Centre
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
09.05.01.02 Etelcalcetide  

Provider notes

  • RFL:
    • Restricted to renal team (Prof Cunningham)
05.01.09 Ethambutol  

Provider notes

  • NMUH:
    • No restriction stated (suspension 400mg/5ml [unlicensed] is available for the treatment of tuberculosis in children)
  • RFL:
    • No restriction stated
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Ethinylestradiol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.03.01 Ethinylestradiol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.01 Ethinylestradiol / dienogest phased pill 28-days Qlaira®

Provider notes

  • RFL:
    • Restricted to Obs and Gynae
07.03.01 Ethinylestradiol / levonorgestrel phased pill 21-days TriRegol®, Logynon®

Provider notes

  • NMUH:
    • Preferred brand = Logynon
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol / levonorgestrel phased pill 28-days Logynon ED®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.01 Ethinylestradiol 20 mcg / drospirenone 3 mg  Eloine®

Provider notes

  • RFL:
    • Preferred brands = Lucette® and Yiznell®
07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg pill 21-days Loestrin 20®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg pill 21-days Gedarel® 20/150, Mercilon®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY = Gedarel 20/150
    • Preferred brand for Obs & Gynae = Mercilon
  • RFL:
    • Preferred brand Munalea®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brand = Mercilon
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg pill 21-days Millinette® 20/75, Femodette®, Juliperla®, Sunya 20/75®

Provider notes

  • NMUH:
    • Preferred brand = Millinette 20/75
    • Millinette 20/75 is restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Preferred brand = Aidulan®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol 30 mcg / norethisterone 1.5mg 21-days Loestrin 30®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg pill 21-days Gedarel® 30/150, Marvelon®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY = Gedarel 30/150
    • Preferred brand for Obs & Gynae = Marvelon
  • RFL:
    • Preferred brand = Munalea®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brand = Marvelon
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg pill 21-days Millinette® 30/75, Femodene®, Sofiperla®, Katya 30/75®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY = Millinette 30/75
    • Preferred brand for Obs & Gynae = Femodene
  • RFL:
    • Preferred brand Aidulan®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brands = Femodene
    • Millinette 30/75= for Community Clinics ONLY
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg pill 21-days Rigevidon®, Microgynon 30®, Levest®, Ovranette®

Provider notes

  • NMUH:
    • Restricted to GU Medicine ONLY = Rigevidon
    • For Obs & Gynae = Microgynon 30
  • RFL:
    • Preferred brands = Microgynon 30 and Maexeni®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brand = Microgynon 30
    • Rigevidon= Formulary item for Community Trust
07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg pill 21-day Cilique®, Cilest®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • There is insufficient information to know if there is an increased risk associated with norgestimate.
04.08.01 Ethosuximide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Ethyl Chloride Cryogesic® Spray

econdary care notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Etilefrine 

Provider notes

  • NMUH:
    • For treatment of priapism in patients with sickle cell disease
    • Etilefrine 25mg Tablets, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.01 Etodolac 

Provider notes

  • NMUH:
    • Restricted to use by Rheumatology Consultants only
  • RFL:
    • Restricted to use by Rheumatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Rheumatology only
10.01.01 Etodolac Modified Release  

Provider notes

  • NMUH:
    • Restricted to use by Rheumatology Consultants only
  • RFL:
    • Restricted to use by Rheumatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Rheumatology only
15.01.01 Etomidate Etomidate-Lipuro®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.01.01 Etomidate Hypnomidate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.03.02.02 Etonogestrel 68mg subdermal implant Nexplanon®

Second-choice parenteral progestogen-only contraceptive (JFC July 2019)

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY.
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.04 Etoposide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Etoricoxib 

Provider notes

  • NMUH:
    • Non-formulary
    •  Check MHRA Drug Safety Updates 
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Etravirine 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Eucerin ® Intensive cream/lotion Urea 10%

Provider notes

  • RFL:
    • 2nd line urea containing emollient
08.01.05 Everolimus Votubia®

DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Approved for renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (July 2013)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Everolimus Afinitor®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • TA432, 449 and 498 do not apply at NMUH as services not offered.
    • See links below
  • RFL:
    • As per NICE guidance (see below)
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.02 Everolimus (compassionate access) Afinitor®

NOTE: There is more than one monograph for Everolimus, click here to search for formulary status and its use for other indications. 

Approved for pancreatic NET (as part of compassionate access program) at RFL only.

02.12 Evolocumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • Restricted to Lipid Clinic
    • Prescriptions are supplied monthly for first 4 months then 3 monthly.  Homecare service also available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.01 Exemestane 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Exemestane is indicated for 3rd line treatment (after tamoxifen and anastrazole) in post-menopausal women with metastatic breast cancer
02.12 Ezetimibe 

Primary hypercholesterolaemia where a statin is contraindicated, not tolerated (consider referral to lipid specialist) or as an adjunct where high intensity statins have failed to sufficiently reduce cholesterol levels

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Restricted to lipid clinic
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of ezetimibe is reserved as a 3rd line agent where treatment with simvastatin, and then atorvastatin has failed, and for patients for whom the use of a statin is contraindicated, or who are statin intolerant, in accordance with the NICE guidance.
02.11 Factor IX 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemophilia centre
    • Alphanine®, Alprolix® (eftrenonacog alfa), Benefix® (nonacog alfa), Idelvion® (albutrepenonacog alfa), Refixia® (nonacog beta pegol)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIIa, recombinant Novo 7®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemophilia centre
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary

 

02.11 Factor VIII 

Provider notes

  • NMUH:
    • PbR (Payment by Results) excluded drug
  • RFL:
    • Available from the Haemophilia centre
    • Advate® (octocog alfa), Elocta® (efmoroctocog alfa), Fanhdi®, Fibrogammin®, Helixate Nexgen® (octocog alfa), Kogenate® (octocog alfa), Novoeight®, Optivate®, Refacto AF® (moroctocog alfa)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIII + von Willebrand factor 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
    • Voncento®, Wilate®, Haemate P®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIII Inhibitor Bypassing Fraction 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
    • Feiba®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIII, recombinant Susoctocog alfa; Obizur®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for acquired haemophilia A in line with NHSE clinical commissioning policy 170061P (RFL only; JFC November 2018)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor X Coagadex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemphilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor XI Hemoleven®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the Haemphilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor XIII Fraction, Dried 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemophilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
05.03.02.01 Famciclovir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Microbiology use only
10.01.04 Febuxostat 

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists or under the direction of a Consultant Rheumatologist.
    • See links below
  • RFL:
    • Restricted to Consultant Rheumatologists in line with NICE TA
  • RNOH:
    • See link below
  • UCLH:
  • WH:
    • As per NICE TA
10.03.02 Felbinac 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
    • Gel 3% available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to the Rheumatology team ONLY
    • Available over the counter without a prescription
02.06.02 Felodipine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
14.04 Fendrix® Hepatitis B vaccine Single Component

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
02.12 Fenofibrate 

Provider notes

  • NMUH:
    • Lipantil stocked
  • RFL:
    • Restricted to Lipid Clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 160mg tablets only
15.01.04.03 Fentanyl 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted Only on the recommendation of the Pain Team for patients intolerant to or with contraindications to morphine and oxycodone
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Fentanyl buccal tablets Effentora®

Provider notes

  • NMUH:
    • Non-formulary 
  • RFL:
    • Approved for the pallative care and pain management team only
  • RNOH:
    • Only on the recommendation of the Pain Team for patients intolerant to or with contraindications to morphine and oxycodone.
  • UCLH:
  • WH:
    • Non-formulary
04.07.02 Fentanyl lozenges Actiq®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Pain Team use and Peri-Operative analgesia only. 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.02 Fentanyl patch 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
21.01 Fentanyl patch 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Fentanyl patch for acute post-operative pain in primary knee replacement surgery
30 patient evaluation at RNOH site only. Evaluation to be reviewed at JFC (April 2015)

04.07.02 Fentanyl sublingual tablets Abstral®

Approved for the treatment of breakthrough, chronic, cancer pain in palliative patients taking opioid agonists, who are unable to obtain relief from, or are intolerant to, oral morphine and oxycodone immediate release. Pain or Palliative Care recommendation only (JFC September 2018).

Provider notes

  • NMUH:
    • Restricted to haematology and palliative care teams only
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
09.01.01.02 Ferric Carboxymaltose Ferinject®

See local guidance for iron replacement

Approved for:

  1. Iron deficient anaemia in Obstetrics (January 2017)
  2. Iron deficient anaemia in adult outpatients only, not in patients in first trimester of pregnancy or for patient on haemodialysis (March 2017)

 

Provider notes

  • NMUH:
    • To be used for day case patients and out patients ONLY
    • See link below for parenteral irons prescribing guideline.
    • Ferinject must be prescribed on the specific Daycase Ferinject prescription form; see link below
    • Note: Parenteral iron is contraindicated in the first trimester of pregnancy. For dose of Ferinject in patients with haemodialysis dependent chronic kidney disease, refer to the summary of prouct characteristics.
    • Check MHRA Drug Safety updates
  • RNOH:
    • No restriction stated
  • RFL:
    • Restricted to Renal units and gastroenterology only
  • UCLH:
    • Restricted to outpatients / daycase / facilitate inpatient discharge
  • WH:
    • Parenteral iron should only be considered if oral therapy has failed due to lack of patient co-operation, severe gastrointestinal side effects, continuing severe blood loss or malabsorption. Provided oral therapy is taken reliably and is absorbed, then the haemoglobin response is not significantly faster with the parenteral route.
17 Ferric subsulphate solution  Monsels

Approved as a haemostatic agent in colposcopy (JFC January 2019)

Provider notes

  • NMUH:
    • As above
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As above
09.01.01.01 Ferrous fumarate 

Provider notes

  • NMUH:
    • No restriction stated (not Galfer)
  • RFL:
    • Non-formulary
  • RNOH:
    • Oral syrup available as 140 mg/5mL
  • UCLH:
  • WH:
    • Oral syrup available as 140 mg/5mL (ONLY formulation available)
09.01.01.01 Ferrous fumarate + Folic acid Pregaday®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.01.01.01 Ferrous gluconate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Ferrous gluconate contains a lower content of elemental iron and therefore may be better tolerated than ferrous sulphate.
09.01.01.01 Ferrous sulphate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • First choice for iron-deficiency anaemia
  • UCLH:
  • WH:
    • No restriction stated
09.01.01.01 Ferrous sulphate modified release Ferrograd®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.01 Fexofenadine 

Additionally approved for the treatment of chronic spontaneous urticaria at a 'high dose' for patients who do not respond to 'high dose' cetirizine (JFC November 2018).  Notes: initiate at 180mg daily and increase according to response to a maximum of 360mg twice-daily (720mg daily).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • As above
17.01 Fibrin Sealant Evicel®

Approved for Dura matter closure (July 2015)


Provider notes

  • RNOH:
    • Restricted for soft tissue sarcoma surgery, primary bone tumour surgery, complex revision hip and knee surgery and dura mater closure
  • RFL:
    • Renal / Urology surgery
17.01 Fibrin Sealant Tisseel® Ready to Use

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For use in Vascular / Opthalmology surgery
  • RNOH:
  • UCLH:
  • WH:
  • MEH approvals:
    • Approved for conjunctival surgery in preference to sutures for pterygium surgery (January 2013)
21.01 Fibrin sealant Artiss®

Simple mastectomies - as part of the '23 hour mastectomy' pathway
Under evaluation at RFL only (October 2017)

Provider notes

  • RFL:
    • See above
05.01.07 Fidaxomicin 

Consultant microbiologist approval only for multiple recurrent Clostridium difficile infections (at least three). Fidaxomicin could also be used in patients in extremis when all other drugs had failed (October 2012)

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Consultant microbiologist approval only  
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
09.01.06 Filgrastim Neupogen®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • From June 2019 - Accofil® is the preferred brand
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.06 Filgrastim Zarzio®

Provider notes

  • NMUH:
    • Check MHRA Drugs Safety Alerts
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Requires HAEMATOLOGIST approval
    • Store in a refrigerator
  • UCLH:
  • WH:
    • No restriction stated
06.04.02 Finasteride 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Urology use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Finasteride should be initiated by urology only for the treatment of patients with BPH in whom alpha-blockers have failed.
08.02.04 Fingolimod 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drug Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.04.02 Flavoxate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.03.02 Flecainide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.03 Flecainide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Specialist use only
21.01 Florbetapir F 18 injection 

Amyvid (florbetapir) for Alzheimer's disease
10 patient evaluation at RFL site only. Evaluation to be reviewed at JFC (JFC September 2014 and February 2015)

17.01 Flowable haemostatic agent with thrombin Surgiflo®

Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016)

17.01 Flowable haemostatic agent with thrombin Floseal®

Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016)

Provider notes

  • RFL:
    • Renal / Urology surgery
13.04 Flucinolone Acetonide 0.0025% - Topical Synalar 1 in 10 Dilution®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
05.01.01.02 Flucloxacillin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.02 Fluconazole 

Provider notes

  • NMUH:
    • Infusion restricted to Microbiology Consultants use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted antifungal. Microbiology approval only
05.02 Flucytosine 

Provider notes

  • NMUH:
    • Restricted to Microbiology Consultants use only
  • RFL:
    • Microbiology approval required 
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Microbiology approval only
20 Flucytosine tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 500mg tablets
08.01.03 Fludarabine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.03.01 Fludrocortisone 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Fludroxycortide - topical Haelan®

Provider notes

  • NMUH:
    • Haelan tape is FORMULARY, for use on keloid scars only.
    • Haelan cream and Haelan ointment are NON-FORMULARY.
  • RFL:
    • Restricted to Dermatologists only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tape only
15.01.07 Flumazenil 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Flumazenil is used to reverse the sedative effects of benzodiazepines in anaesthetic, intensive care and diagnostic procedures. It should not be used for routine benzodiazepine reversal. It has a shorter half-life than diazepam and midazolam and care is required to avoid the risk of resedation.
12.01.01 Flumetasone 0.02% + Clioquinol 1% ear drops Locorten-Vioform®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.02.01 Flunisolide Syntaris®

Provider notes

  • RFL:
    • No restriction stated
13.04 Fluocinolone acetonide 0.00625% - Topical Synalar 1 in 4 Dilution®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • cream and ointment
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Fluocinolone acetonide 0.025% - Topical Synalar®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Cream, ointment and gel available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Gel 0.025% (Synalar) 30g ONLY
13.04 Fluocinolone acetonide 0.025% + Clioquinol 3%- Topical Synalar C®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Cream and Ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.04.01 Fluocinolone acetonide intravitreal implant Iluvien®

 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Diabetic macular oedema after an inadequate response to prior therapy (Nov 2013 TA301)
13.04 Fluocinonide 0.05% - Topical Metosyn®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • cream and ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 FluorEscein 20% injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
  • UCLH:
  • WH:
11.08.02 Fluorescein eye drops - unit dose 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 1% fluorescein sodium is not kept at RFH
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 2% only
11.08.02 Fluorescein paper strips 1mg 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.05.03 Fluorides En-De-Kay® Tablet

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Islington Community Only - direct ward delivery
09.05.03 Fluorides En-De-Kay® Oral Drops

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Islington community only
09.05.03 Fluorides Duraphat® Toothpaste

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 0.619% toothpaste available for Simmons House and Islington community clinics only 
17 Fluorocholine-18F 

Provider notes

  • RFL:
    • PETC/CT imaging for staging of prostate cancer (RFL only, September 2013)
11.04.01 Fluorometholone 0.1% eye drops FML®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.08.01 Fluorouracil 5% cream Efudix®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.03 Fluorouracil injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.03 Fluoxetine 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Caps 20mg. Liquid 20mg/5ml. Only
  • CIFT approvals:
    • Depression
    • 1st/2nd line for Generalised Anxiety Disorder (GAD) (off-label)
    • 1st/2nd line for panic disorder (off-label)
    • 1st/2nd line for social anxiety disorder
  • BEHMT approvals:
    • Depression
04.02.02 Flupentixol decanoate depot injection Depixol® Conc.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Flupentixol decanoate depot injection Depixol® Low Volume

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Flupentixol decanoate depot injection Depixol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.01 Flupentixol tab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • Depot injection only
04.03.04 Flupentixol tab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Initiate after discussion with liaison psychiatry team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT approvals:
    • Depression
  • BEHMT approvals:
    • Depression
04.02.02 Fluphenazine decanoate depot injection Modecate®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Fluphenazine decanoate depot injection Modecate Concentrate®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
08.03.04.02 Flutamide 

Provider notes

  • NMUH:
    • Restricted to Consultant Oncologist and Urologist use only
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
03.02 Fluticasone furoate + Vilanterol inhaler Relvar Ellipta®

Approved for:

  • COPD (JFC February 2017)
  • Asthma (JFC May 2017)
  • Adolescent asthma; age 12-19 (JFC May 2019)

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • As per agreed indications above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.02.01 Fluticasone furoate 27.5mcg/spray nasal spray 

Provider notes

  • NMUH:
    • Restricted for use in paediatric patients ONLY
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Fluticasone inhaler (DPI) 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as first-line choice (before budesonide nasules) for eosinophilic oesophagitis in adults. Fluticasone Accuhaler (dry powder inhaler) '250' should be sucked 1-2 doses twice daily and down titrate dose for maintenance dosing (JFC February 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
03.02 Fluticasone inhaler (pMDI + DPI) Flixotide®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Paediatric Consultants use only.
  • RFL:
    • See NCL Adult Asthma Inhaler Choice Guidelines
    • MDI - 50mcg/125mcg/250mcg stocked
    • Accuhaler - 100mcg/250mcg/500mcg stocked
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Turbohalers, Accu-halers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
    • 50 micrograms, 125 micrograms, 250 micrograms/metered inhalation CFC-Free (Flixotide Evohaler) & Accu- haler 500 micrograms/ metered inhalation ONLY
13.04 Fluticasone propionate - Topical Cutivate®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to paediatrics only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.02 Fluticasone propionate + Formoterol inhaler (pMDI) Flutiform®

Approved for asthma requiring a combined ICS/LABA (May 2013)

  • NMUH:
    • See links below
  • RFL:
    • See NCL Adult Asthma Inhaler Choice guidelines
    • 50/5, 125/5 and 250/10 MDI stocked
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
03.02 Fluticasone propionate + Salmeterol inhaler AirFluSal Forspiro®

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
03.02 Fluticasone propionate + Salmeterol inhaler (pMDI + DPI) Sirdupla®, Seretide®

Provider notes

  • NMUH:
    • See links below
    • Seretide 125 & 250 Evohalers and are NON-FORMULARY, except in paediatric patients.
    • Seretide 500 is non-formulary. AirFlusal Fospiro 50/500 should be used instead. See link below for further information.
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Approved for prescribing by Respiratory Team only. All pharmacists must ensure inpatients have been reviewed by Respiratory Nurse Specialist before supplying prior to prescribing.
12.02.01 Fluticasone propionate 400mcg/unit nasal drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.02.01 Fluticasone propionate 50mcg/spray nasal spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
20 Fluticasone propionate nasules / nasal spray 

Approved for Oral lichen planus after failure of betamethasone (JFC June 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Indicated for oral linchen planus (OLP) only
02.12 Fluvastatin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to liver and renal patients only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.03.03 Fluvoxamine Maleate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.02 Folic Acid 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • When used in combination with oral methotrexate various regimens are used from once-weekly, twice-weekly to daily use (except on day of methotrexate)
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Folic acid is indicated in confirmed folate deficiency due to dietary lack, gastrointestinal disease, pregnancy, chronic haemolytic states, myeloproliferative disorders, haemodialysis, and parenteral nutrition, intensive care of the very sick patient or in premature infants. Folic acid can be used to correct serious haematological changes caused by dihydrofolate reductase inhibitors (DFRIs), after the DFRI has been discontinued. Examples of DFRIs include trimethoprim and co-trimoxazole.
    • Before treating megaloblastic anaemia with folic acid alone, vitamin B12 deficiency MUST be excluded. Folic acid may relieve the haematological features of vitamin B12 deficiency and allow neuropathy to develop undetected. If treatment must be started immediately, both folic acid and hydroxocobalamin should be given.
08.01.05 Folinic acid + fluorouracil + irinotecan (FOLFIRI) 

Approved for:

  • 2nd / 3rd line treatment of inoperable gasto-oesophageal adenocarcinoma (May 2015)
  • 2nd line for high grade neuroendocrine tumour (March 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
08.01.05 Folinic acid + fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) 

Approved for 1st line treatment of unresectable metastatic colorectal cancer (May 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
08.01.05 Folinic acid + fluorouracil + oxaliplatin + irinotecan (mFOLFIRINOX) 

Approved adjuvant treatment of pancreatic cancer (JFC September 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
02.08.01 Fondaparinux 

Provider notes

  • NMUH:
    • Restricted to use for patients with Unstable Angina / NSTEMI.
    • See Trust Guideline on use
  • RFL:
    • Restricted to use for patients with Unstable Angina / NSTEMI
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted for use in unstable angina and NSTMEI
03.01.01.01 Formoterol fumarate inhaler (DPI) Oxis® Turbohaler

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Turbohalers, Accuhalers and Autohalers are reserved for patients unable to tolerate an MDI with spacing device.
A2.02.02.03 Forticreme Complete 

Provider notes

  • NMUH:
    • Stroke, Dysphagia, fluid restrictions, CAPD, HD, Disease related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished, inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagiaSemi-solid. High in protein. For dysphagia or requiring a soft diet, tolerating low volume of food
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.03 Fortisip Compact Protein 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Fosamprenavir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
20 Foscarnet sodium 2% cream 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
  • UCLH:
  • WH:
05.03.02.02 Foscarnet sodium IV 

Provider notes

  • NMUH:
    • Restricted for HIV patients use only.
  • RFL:
    • Restricted to HIV; Transplant patients; Haematology; Oncology
    • Virology approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.07 Fosfomycin intravenous 

Microbiology approval only for treatment of infections, or suspected infections, caused by multi-drug resistant Gram-negative organisms, including ESBLs (JFC August 2016)

Provider notes

  • NMUH:
    • Should only be prescribed following advice from a Consultant Microbiologist
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
05.01.07 Fosfomycin oral sachets 

Approved for prescribing in primary and secondary care for symptomatic UTI sensitive to fosfomycin, where patients are unable to receive, or the organism is resistant to, first-line antibiotics (July 2015)

Provider notes

  • NMUH:
    • Consultant Microbiology approval only
  • RFL:
    • As per Microguide for UTI
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
08.03.04.01 Fulvestrant 

Approved as Third-line therapy for locally advanced or metastatic HER2-, ER+ breast cancer in postmenopausal women without symptomatic visceral disease, that has recurred or progressed after a non-steroidal aromatase inhibitor and tamoxifen (JFC February 2016).

Provider notes

  • NMUH:
    • To be prescribed by Oncology Consultants ONLY
    • See indication above
  • RFL:
    • Approved as per above
    • Approved as per NICE TA593 in combination with ribociclib
    • Approved as per NICE TA597 in combination with abemaciclib
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See indication above
13.05.02 Fumaric acid esters Fumaderm ®

Provider notes

  • RFL:
    • Approved for dermatology
    • See local protocol
02.02.02 Furosemide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.03.01 Fusidic Acid 1% gel 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For Staph aureus eye infections.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Paediatrics and Ophthalmology out-patients
04.07.03 Gabapentin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Second choice agent for neuropathic pain after first-line amitriptyline.

 Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Second choice agent for neuropathic pain
  • UCLH:
  • WH:
    • Second choice agent for neuropathic pain; also for orthopaedics - post surgery
04.08.01 Gabapentin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist
    • Neurontin available as 100mg and 300mg capsules
04.11 Galantamine 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.11 Galantamine modified release 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.03.03 Ganciclovir 0.15% ophthalmic gel 
  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.03.03 Ganciclovir intravitreal injection 

 Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is an unlicensed special and restricted to Ophthalmology
05.03.02.02 Ganciclovir IV 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to HIV; Haematology; Oncology; Liver and Renal Transplants; Other immunosuppressed patients
    • Virology approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Check with Microbiology
05.03.02.02 Ganciclovir oral 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Check with Microbiology
01.01.02 Gastrocote® 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.01.02 Gaviscon Advance® suspension 

Provider notes

  • NMUH:
    • Gaviscon Advance Tablets are non-formulary and will not be stocked
    • Gaviscon Advance suspension is formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suspension only available
01.01.02 Gaviscon Infant® 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Gefitinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology Team ONLY.
    • See links below
  • RFL:
    • Approved for non-small cell lung cancer in line with NICE
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to the treatment of NSCLC with EGFR mutation.
09.02.02.02 Gelatin intravenous infusion Gelaspan®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Used at BCF
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.02.02.02 Gelatin intravenous infusion Geloplasma®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.02.02.02 Gelatin intravenous infusion Volplex®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.02.02.02 Gelatin intravenous infusion Gelofusine®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Used at RFH
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.03 Gemcitabine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • TA389 NOT APPLICABLE TO TRUST AS SERVICE IS NOT PROVIDED
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.01 Gemcitabine + oxaliplatin 

Gemcitabine + oxaliplatin for biliary tract cancer where cisplatin is contraindicated
Approved under evaluation at RFL only (July 2014)

11.03.01 Gentamicin 0.3% drops Ophthalmic

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for bacterial keratitis.
    • Gentamicin 0.3% eye drops (preservative free) and Gentamicin 0.3% eye drops available.
    • Renal use - see PD antibiotic policies
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.01.01 Gentamicin 0.3% drops Ear

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.03.01 Gentamicin Forte 1.5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Gentamicin Forte 1.5 % Eye Drops 10 ml Bottle and Gentamicin Forte WITHOUT PRESERVATIVE available 
    • These are unlicensed specials and restricted to Ophthalmology for the treatment of bacterial keratitis.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Gentamicin Forte 1.5 % Eye Drops 10 ml Bottle and Gentamicin Forte WITHOUT PRESERVATIVE available 
    • These are unlicensed specials and restricted to Ophthalmology.
05.01.04 Gentamicin injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Refer to gentamicin prescribing guidelines in Microguide
  • RNOH:
    • Different brands of gentamicin 80mg in 2mL vials are stocked at RNOH
    • The Amdipharm, Hospira and Sanofi brands are licensed for administration intramuscularly (IM) and intravenously (IV) and will be kept as stock in all ward areas.
    • The Wockhardt brand is licensed for intravenous route (IV) only and will be stocked in Theatres only. This formulation must not be administered intramuscularly.
  • UCLH:
  • WH:
    • No restriction stated
12.03.05 Glandosane® oral spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Glandosane may be prescribed by an accredited Speech and Language Therapist.
08.02.04 Glatiramer acetate 

Approve for relapsing-remitting multiple sclerosis inline with NHS England Commissioning (JFC Feb 2016).

Brabio® is the preferred brand.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NHSE clinical commissioning policy
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For relapsing-remitting multiple sclerosis, see above
05.03.03.02 Glecaprevir + Pibrentasvir 

Provider notes

  • NMUH:
    • This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
  • RFL:
    • Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.02.01 Glibenclamide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Glibenclamide can cause profound hypoglycaemia, especially in the elderly
06.01.02.01 Gliclazide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Gliclazide has been reported to cause less weight gain than other Sulphonylureas.
    • Tolbutamide and Gliclazide are the drugs of choice in renal impairment.
    • Tolbutamide is short acting. Gliclazide is longer acting and is principally metabolised and inactivated in the liver.
06.01.02.01 Glimepiride 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Glimepiride is available for supply on consultant signature only, for the treatment of overweight Type II diabetics, or those with compliance problems.
06.01.02.01 Glipizide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the diabetes team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.04 Glucagon GlucaGen® HypoKit

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
  • UCLH:
  • WH:
    • No restriction stated
A2.07 Glucose 

Provider notes

  • NMUH:
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.04 Glucose gel 40% GlucoGel®, Glucoboost®

Provider notes

  • NMUH:
    • Glucoboost is stocked at NMUH
  • RFL:
    • Non-formulary
  • RNOH:
    • For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
  • UCLH:
  • WH:
    • Non-formulary
09.02.02.01 Glucose Intravenous 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Glucose 5% (50 mL, 100 mL, 250 mL, 500 mL and 1000 mL)
    • Glucose 10% (500 mL)
    • Glucose 20% (500 mL)
    • Glucose 50% (50 mL)
  • RNOH:
    • Glucose 5% (100 mL, 250 mL, 500 mL and 1000 mL)
    • Glucose 10% (500 mL)
    • Glucose 20% (500 mL)
    • Glucose 50% (50 mL)
    • Glucose 1% in compound sodium lactate (Hartmann's) (1000 mL)
  • UCLH:
  • WH:
    • No restriction stated
06.01.06 Glucose urine test strip Diastix®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.07 Glutaraldehyde 10% solution Glutarol®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.02 Glycerol (Glycerin) 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suppositories 1 g, 2 g, 4 g
11.99.99.99 Glycerol eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is unlicensed and restricted to Ophthalmology
02.06.01 Glyceryl trinitrate parenteral 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.07.04 Glyceryl Trinitrate rectal ointment 

Provider notes

  • NMUH:
    • Rectogesic brand
  • RFL:
    • Rectogesic brand
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Rectogesic brand is first choice for anal fissures (4mg/g)
02.06.01 Glyceryl trinitrate short-acting (tablets and sprays) 

Provider notes

  • NMUH:
    • Nitrolingual Pumpspray and 500mcg sublingual tablets available
  • RFL:
    • Only 500 microgram tablets and 400 microgram spray kept at the RFH.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Sublingual tablets 500 micrograms and 400 microgram spray available at WH
02.06.01 Glyceryl trinitrate transdermal 

Provider notes

  • NMUH:
    • Restricted to venous cannulation use only.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.04 Glycine 1.5% Irrigation Solution 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Available as 3L bags
  • RNOH:
    • Available as 3000 mL bags
  • UCLH:
  • WH:
    • No restriction stated
15.01.03 Glycopyrronium injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.12 Glycopyrronium powder Robinul®

Provider notes

  • RFL:
    • Approved for use in dermatology and Mr Baker's clinic for the treatment of hyperhidrosis
13.12 Glycopyrronium solution for iontophoresis 

Provider notes

  • RFL:
    • Approved for use by Dermatology - paediatric use
13.12 Glycopyrronium tablets 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Unlicensed - 1mg and 2mg tablets available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Glycopyrronium tablets  

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Unlicensed - 1mg and 2mg tablets available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.03 Golimumab 

See NCL treatment pathway for place in therapy (note: biosimilar adalimumab and biosimilar infliximab are preferred anti-TNFs; JFC April 2019).

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update.
    • See links below.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Consultant Gastroenterologists
    • NICE TA329 applies
10.01.03 Golimumab 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Restricted to Consultant Rheumatologists
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • Restricted to Rheumatology
    • Approved for use in RA, AS and PsA in line with NICE guidance
  • RNOH:
    • Rheumatology Consultants ONLY.
  • UCLH:
  • WH
    • As per NICE TA and above
06.05.01 Gonadorelin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.07.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Preferred product is leuprorelin
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Goserelin is reserved for the treatment of breast cancer only
A5.02.04 Granuflex 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Hydrocolloid dressing 10 cm * 10 cm (10), 20 cm * 20 cm (5) &amp; Border dressing 10 cm * 13 cm (5), 15 cm * 15 cm (5) only
A5.02.01 GranuGel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
03.04.02 Grass and Tree Pollen Extract Pollinex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for grass/tree-pollen seasonal allergic rhinitis requiring treatment with subcutaneous immunotherapy; restricted to RLHIM/RNTNE allergy clinics for patients experiencing adverse reactions to the allum content of Allergovit  and UCLH paediatric allergy clinics as first line (UCLH only; JFC November 2018)
  • WH:
    • Non-formulary
05.02 Griseofulvin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.10.02 Griseofulvin 400mcg/spray Grisol AF®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.05.03 Guanethidine monosulphate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Guselkumab 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.02 Haem Arginate Normosang®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
20 Haemophilus influenzae type B Combined Vaccine Menitorix®

Approved as Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
  • WH:
    • Non-formulary
01.07.01 Haemorrhoid relief ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Anusol
  • RNOH:
    • Generic 'Haemorrhoid relief ointment'
  • UCLH:
  • WH:
    • Anusol
04.02.01 Haloperidol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Mania
  • BEHMT approvals:
    • Non-formulary
04.02.02 Haloperidol depot injection Haldol Decanoate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
14.04 Havrix Monodose® Hepatitis A vaccine Single Component

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
14.04 HBvaxPRO® Hepatitis B vaccine Single Component

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.03 Helicobacter Test INFAI 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.08.01 Heparin calcium 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.08.01 Heparin sodium 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.08.01 Heparin sodium flush (10 units / mL) 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
13.13 Heparinoid 0.3% Hirudoid®

Provider notes

  • NMUH:
    • Cream is formualry and gel is non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.04 Hepatitis A vaccine with typhoid vaccine Hepatyrix®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.05.02 Hepatitis B immunoglobulin for intramuscular use 

Provider notes

  • NMUH:
    • Available from Health Protection Agency
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Available from Microbiology (Ext 5084)
14.05.02 Hepatitis B immunoglobulin for intravenous use Hepatect® CP

Provider notes

  • RFL:
    • Restricted to Hepatology
    • See liver transplant protocol for more information
13.10.05 Histoacryl® 

Provider notes

  • NMUH:
    • Restricted for use by Gastroenterology Consultants.
  • RFL:
    • Cleared for A+E
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.05 Homatropine 1% eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.05 Homatropine 1% eye drops - preservative free 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preservative free Eye-drops Eye-drops 1% (Moorfields’ special)
02.11 Human fibrinogen Riastap®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.05.01 Human Menopausal Gonadotrophins Menogon®

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated

 

21.01 Human papillomavirus vaccine Gardasil®

Guardasil (HPV) vaccine for recalcitrant warts
5 patient evaluation at RFL site only (March 2013)

21.01 Hyaluronic acid injection Ostenil Plus®

Hyaluronic acid injection (Ostenil Plus) to prevent surgery
Approved under evaluation at RNOH only (July 2014)

RNOH: Restricted for use in accordance with the evaluation protocol by consultants in the Shoulder and Elbow Unit

10.03.01 Hyaluronidase 

JFC approved for epidurolysis (epidural lysis of adhesions, adhesiolysis) for the treatment of chronic pain in patients presenting with radicular pain (JFC October 2016)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.05.01 Hydralazine 

 Primary care notes

GP-Red Red Hydralazine injection is for hospital prescribing only

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
A5.02.04 Hydrocoll Border 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Hydrocortisone - Topical 

 Provider notes

  • NMUH:
    • Hydrocortisone 2.5% Ointment is FORMULARY.
    • Hydrocortisone 2.5% cream is NON-FORMULARY.
    • All other strength are available as both cream and ointment.
  • RFL:
    • 2.5% cream available
    • 0.5% and 1% available in both cream and ointment
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.03.02 Hydrocortisone sodium phosphate Efcortesol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.03.02 Hydrocortisone sodium succinate Solu-Cortef®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone 0.25% + Crotamiton 10% - Topical Eurax-Hydrocortisone®

Provider notes

  • RFL:
    • No restriction stated
13.04 Hydrocortisone 0.5% + Nystatin + Benzalkonium + Dimeticone - Topical Timodine®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Non-formulary
13.04 Hydrocortisone 1% + Clotrimazole 1% - Topical Canesten HC®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.04 Hydrocortisone 1% + Miconazole 2% - Topical Daktacort®

Provider notes

  • NMUH:
    • Datkacort Cream is FORMULARY
    • Daktacort Ointment is NON-FORMULARY
  • RFL:
    • Both cream and ointment available
  • RNOH:
    • Store Daktacort cream in the refrigerator 
  • UCLH:
  • WH:
    • No restriction stated
12.01.01 Hydrocortisone 1% + Neomycin ear drops Otosporin®

Provider notes

  • RFL:
    • No restriction stated
13.04 Hydrocortisone 1% + Nystatin + Chlorhexidine - Topical Nystaform-HC®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone 1% + Urea 10% - Topical Alphaderm®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.02.02 Hydrocortisone acetate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone Acetate 1% + Fusidic Acid 2% - Topical Fucidin H®

 

Provider notes

  • NMUH:
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
01.05.02 Hydrocortisone acetate rectal foam Colifoam®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.03.01 Hydrocortisone buccal tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone butyrate - Topical Locoid®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • cream, lipocream, ointment and scalp lotion available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Cream 0.1% 30g, Ointment 0.1% 30g, Lotion 0.1% 30ml ONLY
06.03.02 Hydrocortisone tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.03.04 Hydrogen peroxide 6% mouthwash BP 

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.11.06 Hydrogen peroxide cream Crystacide®

Provider notes

  • RFL:
    • Dermatology use only
13.11.06 Hydrogen Peroxide Solution BP 

Provider notes

  • NMUH:
    • 3% solution stocked at NMUH
    • Check MHRA drug safety updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Solution 3% ONLY
13.02.01.01 Hydromol® bath and shower emollient 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Hydromol® cream/ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for the use by Consultant Dermatologists ONLY
    • Ointment 125g, 500g available
04.07.02 Hydromorphone injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Relief of severe pain in cancer - intrathecal use for patients on high-dose intrathecal morphine requiring frequent hospital visits for pump refill or unable to tolerate side-effects. Under the National Neuromodulation Registry (UMC Sept 2016)
  • WH:
    • Non-formulary
04.07.02 Hydromorphone modified release Palladone® SR

Provider notes

  • NMUH:
    • Restricted to Consultant Haematologists and Consultant Oncologists use only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.02 Hydroxocobalamin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
18 Hydroxocobalamin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Hydroxycarbamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.01.03 Hydroxycarbamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Hydroxycarbamide Suspension 50mg/5ml (100 ml) unlicensed preparation is also available
  • RFL:
    • Restricted to Haematology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Hydroxychloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted to Rheumatology Consultants Only
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Hydroxychloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for symptomatic erosive oral lichen planus refractory to topical treatment (corticosteroids or tacrolimus) (JFC June 2018). 

DMARD fact sheet also specifies approval for "Dermatological conditions caused or aggravated by sunlight".

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.01 Hydroxyzine 

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Ucerax brand for syrup only
01.02 Hyoscine butylbromide 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety alerts
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Check MHRA drug safety alerts
15.01.03 Hyoscine Hydrobromide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.06 Hyoscine hydrobromide patches 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.06 Hyoscine hydrobromide tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.07 Hypertonic sodium chloride 3% nebuliser solution MucoClear® 3%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted Item  Restricted for the management of altered respiratory secretions in the spinal injured patient. Requires approval from a member of the Tracheostomy team or an ITU consultant
  • UCLH:
  • WH:
    • Non-formulary
03.07 Hypertonic sodium chloride 7% nebuliser solution Nebusal®

Provider notes

  • RFL:
    • No restriction stated
11.08.01 Hypromellose 0.3% + Dextran 70 0.1% eye drops Tears naturale®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.01 Hypromellose eye drops 

Provider notes

  • NMUH:
    • 0.3% and 1%
  • RFL:
    • 0.3% only
  • RNOH:
    • 0.3%
  • UCLH:
  • WH:
    • 0.3%
11.08.01 Hypromellose eye drops - unit dose 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
06.06.02 Ibandronic Acid 150mg tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
06.06.02 Ibandronic Acid 50mg tablets 

Approved as second-line adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality, for patients without IV access/zolendronic acid toxicity (JFC February 2019).

Provider notes

  • NMUH:
    • 1st line bisphosphonate for the Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
  • RFL:
    • See above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
06.06.02 Ibandronic acid IV infusion 

Approved for prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases (July 2013).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per above inidication
  • RNOH:
    • ???
  • UCLH:
  • WH:
    • Non-formulary
06.06.02 Ibandronic Acid IV injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Ibrutinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotheray prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
10.03.02 Ibuprofen 5 % gel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
10.01.01 Ibuprofen immediate release 

Provider notes

  • NMUH:
    • See MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • First choice NSAID
  • UCLH:
  • WH:
    • Intravenous injection restricted to Consultant level
07.01.01.01 Ibuprofen IV injection Pedea®
  • NMUH:
    • Refer to SPC
  • RFL:
    • Restricted to NICU
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.03 Icatibant 

Approved for treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC June 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For the treatment of hereditary angioedema in line with NHSE comissioning policies
    • Restricted to Immunology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.02 Idarubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.08 Idarucizumab 

For dabigatran reversal. Restricted to patients with who have life/limb threatening bleeding, uncontrolled bleeding, or require emergency surgery (February 2016)

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • As above
    • Haemophilia recommendation only
  • RNOH:
    • No restriction stated
  • UCLH:
    • Kept in blood transfusion lab and restricted to thrombosis haematology consultants only
  • WH:
    • Non-formulary
21.02 Idebenone (free of charge) Raxone®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • EAMS approved for Duchenne’s Muscular Dystrophy for patients in active respiratory decline (%FVCp 80-25%) (UCLH only; September 2018)
  • WH:
    • Non-formulary
08.01.05 Idelalisib 

Idelalisib should not be initiated as a first line treatment in chronic lymphocytic leukaemia (CLL) patients with 17p deletion or TP53 mutation - see 'Direct Communication' below

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Idursulfase 

Provider notes

  • RFL:
    • Restricted to the lysosomal storage disorders unit

 

08.01.01 Ifosfamide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.05.01 Iloprost injection  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in pulmonary hypertension, scleroderma and peripheral vascular disease - see local protocols
    • Also approved for use on ITU
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Available on named patient basis only.  Contact pharmacy for further information
02.05.01 Iloprost nebules Vantavis®

Provider notes

  • RFL:
    • approved for use by the pulmonary hypertension team and in ITU for ARDS
08.01.05 Imatinib tabs 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Gilvec for GIST only.

Generic for all other indications.

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
09.08.01 Imiglucerase 

Provider notes

  • RFL:
    • Restricted to the lysosomal storage disorders unit
05.01.02.02 Imipenem + Cilastatin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Microbiology approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.03.01 Imipramine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Depression
  • BEHMT approvals:
    • Depression
13.07 Imiquimod 3.75% cream Zyclara®

Approve for actinic keratosis (AK) and basal cell carcinoma (BCC) (JFC March 2013)

Provider notes

  • NMUH:
    • Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second line options (following treatment with fluorouracil): Zyclara for surface area >25cm2, Aldara for surface area <25cm2
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.07 Imiquimod 5% cream Aldara®

Provider notes

  • NMUH:
    • Restricted to Dermatology and GU Consultants
    • Approved for treatment of Superficial basal cell carcinoma, as a second line option, where fluorouracil treatment is contraindicated or has not been tolerated.
    • Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second-line options (following treatment with fluorouracil): Aldara for surface area <25cm2, Zyclara for surface area >25cm2
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.04 Inactivated Influenza Vaccine (Split Virion) 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.03.02 Inadine (Povidone-iodine) 

Provider notes

  • NMUH:
    • 9.5 x 9.5 cm is stocked at NMUH
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.02.01 Indapamide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.02.01 Indapamide modified release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Indometacin immediate release 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Restricted to Neurology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Indometacin Modified Release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Rheumatology only
20 Indometacin suppositories 

Approved for tocolytic therapy during pre-natal repair of myelomeningocele, a serious form of spina bifida (UCLH only; JFC February 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • As tocolytic therapy during pre-natal repair of myelomeningocele (fetal spina bifida) (UMC Dec 2017)
  • WH:
    • Non-formulary
07.04.01 Indoramin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Urology use only
  • RFL:
    • Restricted to urology only. Only 20mg tablets kept at the RFH.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.11.01 Industrial Methylated Spirit BP 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
14.04 Infanrix Hexa® Diphtheria, tetanus, pertussis, poliomyelitis (inactivated), hepatitis b (rDNA) and Hib

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
14.04 Infanrix-IPV+Hib® Diphtheria, Tetanus, Pertussis [Acellular, Component], Poliomyelitis [Inactivated] and Haemophilus T

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
A2.01.03.02 Infatrini 

Provider notes

  • NMUH:
    • Infatrini (Nutricia Clinical) Liquid (sip or tube feed) per 100mL
    • For ages 0-12 months to increase calorie intake to meet requirements and for growth.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.03 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the preferred brand

 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update
  • RFL:
    • Restricted to Consultant Gastroenterologists for NICE approved indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Consultant Gastroenterologists
    • NICE TA163, TA187 and TA329 applies

 

10.01.03 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the brand of choice

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists
    • See links below.
    • Check MHRA Drug Safety Updates.
  • RFL:
    • Approved for use in RA, AS, PsA (in line with NICE), Sarcoid (seek pharmacy advice) and Hidradenitis Suppurativa (NHSE)
    • Approved for use in neurosarcoid (Dr Kidd only)
  • RNOH:
    • Restricted for Rheumatology Consultants ONLY.
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the preferred brand

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Restricted to Consultant Dermatologists 
    • See MHRA Drug Safety Updates
  • RFL:
    • Approved for use in the treatment of Psoriasis and Hydradenitis Suppurativa (NHSE)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted
20 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the preferred brand.

Approve for steroid-refractory ipilimumab-induced colitis (August 2016)

06.01.01.03 Injection Devices Autopen®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.03 Injection Devices HumaPen® Luxura

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.13 Inotersen injection 

See NICE HST for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the amyloidosis clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.01.01 Insulin Humulin® S

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.01 Insulin Actrapid®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.01 Insulin Aspart  NovoRapid®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • For use in accordance with RNOH Hyperglycaemia Protocol for Type 1 Diabetes Mellitus (see link below)
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Insulin degludec Tresiba®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for patients with Type 1 diabetes who had
(i) intermittent adherence to basal insulin leading to recurrent DKA or HbA1c ≥9.5% despite regular intervention from MDT or
(ii) problematic hypoglycaemia and were not eligible for an insulin pump (JFC November 2017)

 

Provider notes

  • NMUH:
    • Non formulary
    • Check MHRA Drug Safety Updates
  • RFL:
    • See indications above
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • As above
06.01.01.02 Insulin Detemir Levemir®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Initiation as per Diabetes team advice
06.01.01.02 Insulin Glargine 100units/mL Lantus®

For continuation only (new starters to use Abasaglar)

Provider notes

  • NMUH:
    • Check MHRA Safety Alerts
    • See link below
  • RFL:
    • Initiation of therapy under the recommendation of the diabetic team only
    • See link below
  • RNOH:
    • See link below
  • UCLH:
  • WH:
    • As above
06.01.01.02 Insulin Glargine 100units/mL Abasaglar®

Approved for:

  • Type 2 diabetes: First choice analogue basal insulin. See NCL guideline for insulin in Type 2 diabetes guideline
  • Type 1 diabetes


Provider notes

  • NMUH:
    • Check MHRA Safety Alerts
    • See link below for use in Type 2 diabetes
  • RFL:
    • Initiation of therapy under the recommendation of the diabetic team only
    • See link below for use in Type 2 diabetes
  • RNOH:
    • See link below for use in Type 2 diabetes
  • UCLH:
  • WH:
    • Initiation as per Diabetes team advice
06.01.01.01 Insulin Glulisine Apidra®

Provider notes

  • RFL:
    • Restricted to Endocrinology
06.01.01.01 Insulin Lispro Humalog®

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Updates 
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.01 Insulin Lispro 200 units/ml Humalog®
08.02.04 Interferon Alfa IntronA®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Consultant Haematologists and Gastroenterologists only
08.02.04 Interferon Alfa Roferon-A®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Preferred brand for haematology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.02.04 Interferon beta-1a Rebif®

Provider notes

  • RFL:
    • Restricted to neurology for the treatment of MS in line with NHSE clinical commissioning policy
08.02.04 Interferon gamma-1b Immukin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to immunology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.02.01 Intrasite Gel 

Provider notes

  • NMUH:
    • 8g stocked only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.04 Intra-uterine Contraceptive Devices TT 380® Slimline

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.04 Intra-uterine Contraceptive Devices Nova-T® 380

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.04 Intra-uterine Contraceptive Devices T-Safe® 380A QuickLoad

Provider notes

  • NMUH:
    • Restricted to Obs & Gynae and GU Consultants ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.04 Intra-uterine Contraceptive Devices Mini TT 380 Slimline®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.02.03 Intra-uterine levonorgestrel system Kyleena®

Approved as first-line intra-uterine device for contraception (February 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
07.03.02.03 Intra-uterine levonorgestrel system Jaydess®

Not a recommended intra-uterine device for contraception; Kyleena is preferred (JFC February 2019)

Provider notes

  • NMUH:
    • Approved for contraception second-line following unsuccessful fitting of Mirena® device (JFC March 2016)
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA Drug Safety Updates
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Approved for contraception second-line following unsuccessful fitting of Mirena® device (March 2016)
07.03.02.03 Intra-uterine levonorgestrel system Levosert®

Approved as first-line intra-uterine device for (JFC March 2018):

  • heavy menstrual bleeding
  • contraception

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
07.03.02.03 Intra-uterine levonorgestrel system Mirena®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.02.02 Iodine and Iodide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 5% oral solution available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Ipilimumab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.02.02 Ipratropium bromide 0.03% nasal spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.01.02 Ipratropium pMDI and nebuliser solution 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • CFC-free inhaler 20 micrograms/metered inhalation ONLY
02.05.05.02 Irbesartan 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to renal patients only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 1st choice for hypertension / diabetes
08.01.05 Irinotecan Hydrochloride 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • To be prescribed by the Oncology team only.
    • See links below
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.01.01.02 Iron Dextran CosmoFer®

See local guidance for iron replacement

Provider notes

  • NMUH:
    • See link below to access the Trust guidelines on use of parenteral irons for iron deficiency anaemia
    • Check MHRA Drug Safety updates
  • RFL:
    • Renal anaemia
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary 
09.01.01.02 Iron Isomaltoside Monofer®

See local guidance for iron replacement

 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety update
  • RFL:
    • Intravenous iron of choice for patients who require rapid iron administration due to capacity issues or certain pathways e.g. pre-op
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.01.02 Iron Sucrose Venofer®

See local guidance for iron replacement

Provider notes

  • NMUH:
    • See Trust guidelines on use of parenteral irons for iron deficiency anaemia; link below
    • Check MHRA Drug Safety updates
  • RFL:
    • Renal anaemia
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.03.02 Isocarboxazid 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.02 Isoflurane 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.01.09 Isoniazid 

Provider notes

  • NMUH:
    • No restriction stated (Isoniazid elixir 50mg/5mL [unlicensed] available for the treatment of tuberculosis in children)
  • RFL:
    • No restriction stated
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Isophane Insulin Insulatard®

Provider notes

  • NMUH:
    • The fomulary choices are vial, 3ml cartridge and Innolet.
  • RFL:
    • No restriction stated
  • RNOH:
    • First line for patients on a feed or patients that are on high doses of steroids, and require insulin. Available in the EDC Fridge
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Isophane Insulin Humulin® I

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Initiation as per Diabetes team advice
02.07.01 Isoprenaline 

Provider notes

  • NMUH:
    • For refractory bradycardia. Isoprenaline 2.25mg in 2ml injection, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Isoprenaline injection is an unlicensed product
  • RNOH:
    • Unlicensed Isoprenaline 200 micrograms in 1mL injection is an unlicensed product. Store in a refrigerator.
  • UCLH:
  • WH:
    • Reftractory bradycardia
    • Unlicensed product
02.06.01 Isosorbide dinitrate immediate released 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.06.01 Isosorbide dinitrate parenteral 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to cardiac cath lab use only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 0.1% infusion available only
02.06.01 Isosorbide mononitrate 

Provider notes

  • NMUH:
    • 60mg modified release and immediate release 10mg and 20mg tablets available
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • 60mg modified release and immediate release 10mg and 20mg tablets available
13.06.01 Isotretinoin 0.05% + Erythromycin 2% gel Isotrexin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Isotrexin gel is restricted to Dermatology
13.06.01 Isotretinoin 0.05% gel Isotrex®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.06.02 Isotretinoin capsules 

Provider notes

  • NMUH:
    • Restricted to Dermatology
    • Check MHRA Drug Safety Updates
  • RFL:
    • Restricted to Dermatology
    • Follow prescribing advice and important safety information including pregnancy prevention programme (PPP) for females of childbearing potential.  Maximum 30 days treatment at a time
    • Patients who do not qualify for the pregnancy prevention programme (PPP) may be supplied more than one month at a time
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Isotretinoin capsules are restricted to Dermatology prescribing only and are not available in the community unless by special arrangement, for details see data sheet.
01.06.01 Ispaghula Husk 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.02 Itraconazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Oral preparations restricted to Dermatology; HIV; Haematology
    • Intravenous preparations restricted to Haematology and Oncology for prophylaxis
    • Microbiology approval required for all other indications and IV treatment doses
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
02.06.03 Ivabradine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria 

Secondary care notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information.
  • RFL:
    • No restriction stated
  • RNOH:
    • Requires CARDIOLOGIST approval
  • UCLH:
  • WH:
    • Available for prescribing to consultant cardiologists only
    • NICE TA267 applies
13.06 Ivermectin 10 mg/g cream 

Approve for papulopustular rosacea. Suitable for primary and secondary care initiation (JFC July 2016)

Provider notes

  • NMUH:
    • To be prescribed by dermatology ONLY for papulopustular rosacea
  • RFL:
    • To be prescribed by dermatology ONLY for papulopustular rosacea
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • Non-formulary
05.05.07 Ivermectin tablets 

Provider notes

  • NMUH:
    • 3mg tablets available from 'special order'
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Ixazomib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Ixekizumab injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for the treatment of Psoriatic Arthritis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Ixekizumab injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • For Psoriasis in line with NICE guidance
    • Homecare available - usually after first month
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A2.01.01.01 Jevity 

Provider notes

  • NMUH:
    • For patients who require a fibre feed, such as those requiring long-term nutrition support.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.01 Jevity 1.5 kcal 

Provider notes

  • NMUH:
    • For patients requiring higher energy intake or fluid restriction or a shorter feeding period who also need a fibre feed.
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.02 Jevity Plus 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.02 Jevity Plus HP 

Provider notes

  • NMUH:
    • For patients with high protein requirements who need a fibre feed, including those on long-term nutritional support.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.02.06 Kaltostat 

Provider notes

  • NMUH:
    • We stock the following in Pharmacy:Kaltostat 7.5x12cm and 5x5cm, Kaltostat Cavity 2g.
    • Kaltostat cavity should only be used when haemostatis is involved. Otherwise Aquacel ribbon (2x45cm) should be used.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Surgical packing 2 g (5)
10.03.02 Kaolin Poultice 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.01 Ketamine injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
21.01 Ketamine oral solution  

Acute pain unresponsive to opiates (inpatient use only; initiation by Pain team consultant or consultant Anaesthetist)
Evaluation for RFL only (approved by DTC in July-17, ratified by JFC in August-17)

13.10.02 Ketoconazole 2% cream 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology Outpatients only.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.09 Ketoconazole 2% shampoo 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology Outpatients only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.02.02 Ketoconazole 2% vaginal cream Nizoral®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.07 Ketoconazole tablets Ketoconazole HRA®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved as first line in pre-treatment prior to surgery (4-6 weeks prior to surgery) or second line post-surgery in patients with persistent Cushing syndrome (long term treatment)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
21.01 Ketoconazole tablets 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Ketoconazole for metastatic hormone refractory prostate cancer (third-line and beyond)
Approved under evaluation for 10 patients. RFL only (January 2017)

06.01.06 Ketone urine test strips Ketostix®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For outpatient use only
15.01.04.02 Ketorolac 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to anaesthetics
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Ketorolac tablets are not available
11.08.02 Ketorolac 0.5% eye drops Acular®

Approved for:

  • Treatment of inflammation post cataract surgery in patients unable to tolerate topical corticosteroids
  • Prophylaxis of cystoid macular oedema (CMO) in high-risk patients

Provider notes

  • NMUH:
    • Restricted to Consultant Ophthalmologist use only.
  • RFL:
    • Non-formulary
  • RNOH:
  • UCLH:
  • WH:
    • Restricted to ophthalmology
11.04.02 Ketotifen 250mcg/mL eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
02.04 Labetalol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Lacosamide  

For patients refractory to standard AEDs (March 2013)

Provider notes

  • NMUH:
    • Restricted for neurology patients with refractory epilepsy to standard antiepileptic drugs
  • RFL:
    • Restricted to neurology as second line therapy
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist only for refractory epilepsy (adjunctive Tx of partial-onset seizures in adults and adolescents)
01.06.04 Lactulose 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.04 Lactulose 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated.
    • May be used at doses up to 30mL QDS
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Lamivudine 

Provider notes

  • NMUH:
    • Epivir brand only approved for HIV patients
    • Zeffix brand approved for HIV and Hepatitis B patients
  • RFL:
    • Epivir brand approved for HIV patients
    • Zeffix brand approved for Hepatitis B patients
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Epivir brand on formulary
04.02.03 Lamotrigine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
04.08.01 Lamotrigine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Neurology department use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Tabs 25 mg, 50 mg, 200 mg. Dispersible tabs 5 mg, 25 mg, 100 mg. Only
08.03.04.03 Lanreotide Somatuline® LA

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to endocrine and neuroendocrine team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.03 Lanreotide Somatuline Autogel®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to endocrine and neuroendocrine team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.03.05 Lansoprazole 

Provider notes

  • NMUH:
    • See links below
    • Check MHRA Drug Safety Alerts
    • The use of orodispersible tablets is restricted to patients with difficulty in swallowing capsules
  • RFL:
    • Orodispersible tablets restricted to patients with feeding tubes/ difficulty in swallowing tablets
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.02.02 Lanthanum Fosrenol ®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to renal patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Lapatinib 

Provider notes

  • NMUH:
    • Special Funding Approval required - seek advice from Oncology Pharmacist
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.08.01 Laronidase 

Provider notes

  • RFL:
    • Restricted to the lysosomal storage disorders unit
20 LAT gel (Lidocaine 4% + Adrenaline 0.1% + Tetracaine 0.5%) 

Approved for second-line management of pain in children requiring sutures/debridement (JFC February 2018)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • No restriction stated
  • WH:
    • Non-formulary
11.06 Latanoprost 0.005% + Timolol 0.5% Xalacom®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • Combination therapies to be used when compliance / cost issues arise
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Latanoprost 0.005% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For ophthalmologists only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.06 Latanoprost 0.005% eye drops - preservative free 

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes

Provider notes

  • NMUH:
    • Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.03.02 Ledipasvir + Sofosbuvir 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use in the treatment of Hepatits C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Leflunomide 

Provider notes

  • NMUH: 
    • Restricted to Rheumatology Consultants ONLY
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH:
  • WH:
    • Restricted to Rheumatology Consultants ONLY
08.02.04 Lenalidomide 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • All prescriptions must be accompanied by a prescription authorisation form
    • See links below
    • Check MHRA Drug Safety Update
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
    • Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.02 Lenalidomide (free of charge) 

Aggressive relapsed / refractory DLBCL as third/last-line option under compassionate use scheme (March 2015)

09.01.06 Lenograstim Granocyte®

Provider notes

  • NMUH:
    • Restricted for use in paediatric patients ONLY. For Adult patients, use filgrastim (Zarzio) first line.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Lenvatinib caps Kisplyx®

DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Lenvatinib caps Lenvima®

DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for thyroid cancer and hepatocellular carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.01 Letrozole 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Oncology department use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
20 Letrozole 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as a second-line option to induce ovulation in women with WHO group II infertility, following failure of treatment with clomifene citrate (JFC January 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • 2nd line after the failure of clomifene citrate for ovulation induction in women with WHO Group II anovulation
  • WH:
    • As above
06.07.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.07.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.07.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Preferred product for use in prostate, maintenance of fertility and breast cancer women.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Levetiracetam 

Provider notes

  • NMUH:
    • Restricted to Consultant Neurologists only
    • To be used as second line adjunctive treatment of partial seizures with or without secondary generalisation
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist
    • Tabs 250 mg, 500 mg, 1 g. Oral solution 100 mg/ 1 ml only
    • Intravenous infusion also available
    • The infusion is available in the emergency drugs cupboard
11.06 Levobunolol 0.5% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Levobunolol 0.5% eye drops - unit dose 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
15.02 Levobupivacaine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
15.02 Levobupivacaine + Fentanyl 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF: Levobupivacaine 0.125% + Fentanyl 4mcg/ml in 500ml
    • RFH: Levobupivacaine 0.1% + 0.0002% Fentanyl in 100ml
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Levocarnitine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Paediatric solution not kept at the RFH.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.12 Levofloxacin 

Provider notes

  • NMUH:
    • Restricted to Consultant Microbiologist or Consultant Gastroenterologist recommendation
  • RFL:
    • Follow RFL microbiology guidelines for agreed indications
    • Microbiology approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
11.03.01 Levofloxacin 5mg/ml eye drops 
  • NMUH:
    • Non-formulary
  • RFL:
    • Levofloxacin 0.5% eye drops (preservative-free).
    • Restricted to bacterial conjunctivitis, keratitis, post intravitreal injections and corneal abrasions.
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
13.03 Levomenthol in aqueous cream 

0.5%, 1%, 2%

Provider notes

  • RFL:
    • 1% and 2% available
04.02.01 Levomepromazine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • No restriction stated
07.03.05 Levonorgestrel 

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA drug safety updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
20 Levosimendan 

Approved for acutely decompensated severe chronic heart failure who have failed to respond to conventional therapy and failed to respond to or did not tolerate inotropic agents (dobutamine or enoximone) (JFC July 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
06.02.01 Levothyroxine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Oral solution 100 mcg/5ml (adults only) and 50 mcg/5ml available
15.02 Lidocaine + Adrenaline injection Xylocaine®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For emergency caesarean section
12.03.01 Lidocaine 10% spray Xylocaine®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 10% spray Xylocaine®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Lidocaine 2% + Chlorhexidine 0.25% gel Instillagel®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.02 Lidocaine 2.5% + Prilocaine 2.5% cream EMLA®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.07 Lidocaine 4% + Fluorescein 0.25% eye drops - unit dose 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For diagnostic or surgical use only. Not to be given for home use
15.02 Lidocaine 4% cream LMX4®

Approved for topical anaesthetic of first-choice prior to venous cannulation or venepuncture for paediatrics (JFC July 2013)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 4% solution Laryngojet®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 5% + Phenylephrine 0.5% topical solution 

Provider notes

  • NMUH:
    • Formulary for ENT use only
  • RFL:
    • For ENT use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 5% ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
20 Lidocaine infusion 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for chronic pain (JFC July 2018)
    • Approved for use in neurology for the treatment of headaches - see local protocol
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for
      • Chronic pain (RESTRICTED to Pain Management Centre at Cleveland Street for chronic pain; UMC May 2018)
      • Perioperative pain (RESTRICTED to UCH and Westmoreland Street Operating Theatres in line with guideline only; UMC July 2018)
  • WH:
    • Non-formulary
02.03.02 Lidocaine injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH:
    • Ampoules are Formulary but infusions are non formulary.
  • RFL:
    • Lidocaine ampoules and infusion available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Lidocaine injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of lidocaine (lignocaine) 2% cartridge, bupivacaine 0.0625% infusion andropivacaine is restricted to theatres only.
01.06.07 Linaclotide 

Approved for IBS-C in adults where two optimally dosed laxatives (from different classes) and an antispasmodic fail to relieve symptoms. Initiation should be by a Gastroenterologist and reviewed at 4 weeks. Prescribing should be transferred to GPs for ongoing prescribing if found to be effective (JFC May 2017)

Provider notes

  • NMUH:
    • To be prescribed as per the JFC recommendations
  • RFL:
    • See indication above
  • RNOH 
    • No restriction stated
  • UCLH:
  • WH:
    • For gastro consultants only as per JFC May 2017 guidance

 

05.01.07 Linezolid 

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Microbiology approval required
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
06.02.01 Liothyronine 

Provider notes

  • NMUH:
    • Liothyronine injection on formulary
    • Liothyronine tablets may be used for indications other than primary hypothyroidism (e.g. thyroid cancer)
  • RFL:
    • IV only on formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.06 Lipegfilgrastim 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Alternative to GCSF + district nurse administration at WH only for patients who can receive daily GCSF but cannot self-inject (JFC August 2016)

Provider notes

  • NMUH:
    • Non-formulary.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For use by oncology consultants only in patients unable to receive daily GCSF infections or needle phobic patients (D&TC Sept 2016)
13.10.05 LiquiBand® 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Liquid and White Soft Paraffin Ointment, NPF 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.06.03 Liquid Paraffin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.06.04 Liquid paraffin + Magnesium hydroxide oral emulsion, BP 

Provider notes

  • NMUH:
    • Restricted to paediatric consultants only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.01 Liquid Paraffin and Liquid Paraffin light eye drops Lacrilube®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
A2.04.01.02 Liquigen 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Liraglutide Victoza®

Semaglutide is the preferred GLP-1 receptor agonist for type 2 diabetes, when used in line with the NCL Fact sheet (JFC August 2019).

Liraglutide 1.2mg should only be initiated for patients with concurrent gastrointestinal conditions e.g. inflammatory bowel disease (JFC August 2019).

Liraglutide 1.8mg is not recommended (JFC July 2018).

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Restricted to endocrinology.
  • RNOH:
    • Requires initiation by a Diabetes Specialist
  • UCLH:
  • WH:
    • The use of liraglutide is restricted to Diabetology
02.05.05.01 Lisinopril 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.02.03 Lithium Carbonate Camcolit®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • 250mg tablets
04.02.03 Lithium Carbonate Liskonum®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • Non-formulary
04.02.03 Lithium Carbonate Priadel®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • No restriction stated
04.02.03 Lithium Citrate Li-Liquid®

Provider notes

  • NMUH:
    • Lithium Citrate liquid is formulary for those with feeding tubes or swallowing difficulties
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • Non-formulary
04.02.03 Lithium Citrate Priadel® liquid

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Initiate after discussion with liaison psychiatry team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.04.02 Lodoxamide 0.1% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
04.03.01 Lofepramine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Depression 
  • BEHMT approvals:
    • Depression 
08.01.01 Lomustine 

Provider notes

  • NMUH:
    • Restricted to Consultant Oncologists and Haematologists use only
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.04.02 Loperamide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Lopinavir + Ritonavir Kaletra®

Provider notes

  • NMUH:
    • Check Drug Safety Update
  • RFL:
    • As per HIV guidelines
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • For TB / HIV clinic only
03.04.01 Loratadine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
    • High doses may be used in dermatology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.01.02 Lorazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • The injection (4 mg in 1mL) must be stored in a refrigerator
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT approvals:
    • Anxiolytic
    • Rapid tranquillisation
    • Acute phase of mania (off-label)
    • Aggression (off-label)
  • BEHMT approvals:
    • Anxiolytic
    • Rapid tranquillisation
04.08.02 Lorazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • First line for status in paediatrics.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.01.04.01 Lorazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.05.05.02 Losartan 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Alternative (second-line) agent.
    • 25mg and 50mg tablets available only
03.01.05 Low range peak flow meter Mini-Wright®
01.06.07 Lubiprostone 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted Item Restricted
  • UCLH:
  • WH:
    • NICE TA318 applies
08.01.05 Lutetium (177Lu) oxodotreotide injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.03 Lymecycline 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Reserved for Dermatology use only
02.05.01 Macitentan 

Provider notes

  • RFL:
    • approved for use by the pulmonary hypertension team
01.06.04 Macrogols Laxido®, Movicol®, Movicol liquid®

Provider notes

  • NMUH:
    • See link below
    • Movicol stocked
  • RFL:
    • Movicol sachets
  • RNOH:
    • Laxido
  • UCLH:
  • WH:
    • No restriction stated
01.06.05 Macrogols Klean-Prep®

Provider notes

  • NMUH:
    • For use in renal failure/congestive heart failure only
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.05 Macrogols Moviprep®

Approved for bowel evacuation; first-line bowel cleansing agent (Gastroenterology service). 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.04 Macrogols paediatric 

Provider notes

  • NMUH:
    • Restricted to Paediatric Consultants only
    • Movicol Paediatric stocked
  • RFL:
    • Movicol Paediatric stocked
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Paediatrics Only
09.05.01.03 Magnesium Aspartate Magnaspartate®

Approved for magnesium deficiency (JFC March 2017)

Provider notes

  • NMUH:
    • See link below to access Trust Formulary bulletin on oral Magnesium Aspartate
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Second line to NeoMag®
  • WH:
    • First line treatment for hypomagnesaemia (approved by NCL JCF Mar17). Magnesium glycerophosphate only for patients unable to tolerate magnesium aspartate.
09.05.01.03 Magnesium glycerophosphate 4mmol/tablet 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • The BNF states that to prevent recurrence of hypomagnesaemia in adults, oral magnesium may be given in a dose of 24 mmol Mg2+ daily in divided doses. In children aged 1 month to 12 years, the BNF for children recommends that the initial dose of oral magnesium for hypomagnesaemia is 0.2 mmol/kg Mg2+ three times daily, with the dose adjusted as needed. In children aged 12 to 18 years, it recommends that the initial dose is 4 to 8 mmol Mg2+ three times daily, adjusted as needed.
  • UCLH:
  • WH:
    • First line treatment for hypomagnesemia is magnesium aspartate. Magnesium glycerophosphate should only be used for patients unable to tolerate magnesium aspartate.
01.06.04 Magnesium Hydroxide Mixture BP 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF: No restriction (historical use)
    • RFH: Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
09.05.01.03 Magnesium Hydroxide Mixture BP  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
20 Magnesium lactate modified release MagTab®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for renal tubular disorders (RFL only; JFC September 2018).
    • For use in renal tubular disorders outpatients clinic only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.01.03 Magnesium sulfate injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Only magnesium sulphate 50% injection stocked
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of magnesium sulphate inj 10% & 20% are restricted to Obstetrics only.
13.10.05 Magnesium sulfate Paste, BP 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.01.01 Magnesium trisilicate Mixture BP 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.10.04 Malathion 0.5% liquid Derbac-M®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.07 Mannitol inhalation Bronchitol®

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal, however, the service not provided at NMUH.
  • RFL:
    • Restricted to lung function clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
17 Mannitol inhalation  Osmohale®

Approved for for bronchial challenge testing. For diagnostic use in Lung Function Departments (September 2013)

02.02.05 Mannitol IV 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 10% and 20% available
  • RNOH:
    • 10% and 20% (500 mL)
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Maraviroc 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV team only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
21.01 Maribavir 

Maribavir for resistant CMV infections
Approved for 3 patients and then to be reviewed at RFL only (January 2015)

A2.04.01.01 Maxijul Super Soluble 

Provider notes

  • NMUH:
    • Carbohydrate supplement for use for nutritional support and malnutrition, for those tolerating low volume of food 15g = 60kcals Can be added to moist, liquid foods. Can be used by catering to add to pureed foods, soups, puddings to increase calorie content
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.05.01 Mebendazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.02 Mebeverine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • 135mg immediate release tablets and 200mg MR capsules only
06.04.01.02 Medroxyprogesterone Acetate 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 2.5mg, 5mg and 10mg tablets available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tabs 5 mg, 10 mg ONLY
08.03.02 Medroxyprogesterone acetate 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.03.02.02 Medroxyprogesterone acetate 150mg IM injection Depo-Provera®

First-choice parenteral progestogen-only contraceptive (JFC July 2019)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Depo-Provera is licensed for short and long-term contraceptive use and is given every 12 weeks. Injectable progestogens effectively inhibit ovulation, in addition to effects on the endometrium and cervical mucus
10.01.01 Mefenamic Acid 

Provider notes

  • NMUH:
    • Non-formulary
    • See link below
  • RFL:
    • Restricted to Gynaecology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.04.01 Mefloquine 

Provider notes

  • NMUH:
    • Restricted to HIV patients only
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.03.02 Megestrol acetate 

Provider notes

  • NMUH:
    • Restricted to Consultant Oncologists use only
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.01.01 Melatonin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Initiated by the Sleep Disorder Service, second line for up to 13 weeks, after zopiclone, zolpidem, or a benzodiazepine, and prescribing should not be transferred to primary care. (October 2015)

Provider notes

  • NMUH:
    • See indication above
  • RFL:
  • RNOH:
    • See indication above
  • UCLH:
    • See indication above
  • WH:
    • Initiation as above only
04.01.01 Melatonin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for insomnia in learning disability. Specialist initiation and continuation by GP under shared care or fact sheet (JFC October 2016).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • Initiation as above only
  • CIFT approvals:
    • Sleep disorders in patients with learning disabilities
  • BEHMT approvals:
    • Non-formulary (but part of CAMHS formulary)
04.01.01 Melatonin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for insomnia in children (> 2 years) with neurological or developmental disorders. Specialist initiation and continuation in primary care (March 2017) Off label use.

Provider notes

  • NMUH:
    • See indication above
  • RFL:
    • See indication above
  • RNOH:
    • See indication above
  • UCLH:
  • WH:
    • See indication above
04.01.01 Melatonin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for:

  • Sleep disorders caused by visual impairment
    • For use by the NHNN Centre for Neuromuscular Diseases for the management of sleep disorders caused by visual impairment. Patients are transferred from GOSH. Appropriate for GPs to continue prescribing. (October 2015)
  • REM Sleep Behaviour Disorder
    • Initiated by the Sleep Disorder Service and can be transferred to primary care once patients have been stabilised. (October 2015) 
  • Circadian Rhythm Disorders
    • Initiated by the Sleep Disorder Service and can be transferred to primary care once patients have been stabilised.  (October 2015) 

Provider notes

  • NMUH:
    • See indication above
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • Initiation as above only
04.01.01 Melatonin Oral Liquid 1mg/1mL 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted for use as a pre-medication in children prior to CT / MRI scan
    • Unlicensed Oral Liquid 1mg/1mL
  • UCLH:
  • WH:
    • For paediatrics only
10.01.01 Meloxicam 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to use by Rheumatology only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Rheumatology only
08.01.01 Melphalan 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.11 Memantine 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL:
    • Restricted to Mental Health Trust formulary only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.06.06 Menadiol sodium diphosphate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • 10 mg tablets stored in the EDC
  • UCLH:
  • WH:
    • No restriction stated
14.04 Meningococcal group B Vaccine Bexsero®

Approved in line with Public Health England Men B immunisation programme  (JFC August 2015) 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • No restriction stated
  • WH:
    • Non-formulary
14.04 Menitorix® Haemophilus type b and Meningococcal group C conjugate vaccine

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
06.05.01 Menotrophin Merional®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.05.01 Menotrophin Menopur®

Provider notes

  • NMUH:
    • First line treatment option for intrauterine insemination. Second line treatment option for ovulation induction in patients in whom clomifene is ineffective.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.04.04 Mepacrine Hydrochloride 

Provider notes

  • NMUH:
    • Restricted to Rheumatology Consultants
  • RFL:
    • On advice of microbiology or infectious diseases consultants OR
    • Use by Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A5.02.03 Mepitel  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Mepivacaine injection Scandonest Plain®

econdary care notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.02 Mepolizumab 

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal, however, the service is not provided at NMUH.
  • RFL:
    • Approved for use in the treatment of asthma in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.02 Meptazinol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Mercaptamine Cystagon®, Procysbi®

Provider notes

  • RFL:
    • Restricted to renal team
01.05.03 Mercaptopurine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For patients intolerant of azathioprine
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For patients intolerant of azathioprine (N.B. dose reduction required if switching from azathioprine)
    • FBC & LFT monitoring required
08.01.03 Mercaptopurine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.02.02 Meropenem 

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Restricted to Neutropenic sepsis (penicillin allergy) and ITU (microbiology approval required within 48 hours)
    • Microbiology approval for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
01.05.01 Mesalazine Octasa®

Approved for ulcerative colitis. Octasa is the NCL choice of mesalazine (May 2014, April 2015)

Provider notes

  • NMUH:
    • Restricted to Gastroenterologists only
    • Octasa® is the preferred mesalazine preparation at NMUHT.
    • All patients newly initiated on, or requiring dose adjustment of mesalazine, should be prescribed Octasa®.
    • See link below 
  • RFL:
    • Octasa is the preferred mesalazine preparation at RFL.  All newly initiated patients should be prescribed Octasa
  • RNOH:
  • UCLH:
    • Non-formulary
  • WH:
    • Octasa® is the preferred mesalazine preparation at WH.  Newly initiated patients on mesalazine should be prescribed Octasa®
01.05.01 Mesalazine Asacol®

Provider notes

  • NMUH:
    • Restricted Item Restricted: Restricted to Gastroenterologists only
    • Octasa® is the preferred oral mesalazine preparation at NMUHT. All patients newly initiated on, or requiring dose adjustment of mesalazine, should be prescribed Octasa®.
    • See link below  
  • RFL:
    • Oral: Restricted to second-line use only; Octasa® tablets are the preferred choice
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Octasa® is the preferred mesalazine preparation at WH.  Newly initiated patients on mesalazine should be prescribed Octasa®
01.05.01 Mesalazine Pentasa®

Provider notes

  • NMUH:
    • Restricted to Gastroenterologists only
  • RFL:
    • Oral: Restricted to second-line use only; Octasa® tablets are the preferred choice 
    • Enema: First-line choice
    • Suppositories: No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Consultant Gastroenterologists only
01.05.01 Mesalazine Salofalk®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Oral: Non-formulary
    • Enema: Restricted to second-line use only; Pentasa® enemas are the preferred choice
    • Suppositories: No restriction
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Please note: Rectal foam only
01.05.01 Mesalazine  Mezavant® XL

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Use of mesalazine rectal preparations and the Pentasa & Mezavant brands of mesalazine is restricted to Consultant Gastroenterologists only.
01.05.01 Mesalazine suppositories Asacol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01 Mesna 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.02.02 Metanium® barrier preparation 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.07.02 Metaraminol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Unlicensed medicine. Available on a named patient basis only.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Metaraminol inj is available for use by anaesthetists only
06.01.06 Meters FreeStyle®
  • NMUH:
    • Optium Neo H meter stocked
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.02 Metformin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated (metformin liquid is non-formulary)
    • See link below 
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.02.02 Metformin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for patients with Type 1 diabetes with a high BMI who want to achieve weight loss (September 2015)

Provider notes

  • NMUH:
    • No restriction stated (metformin liquid is non-formulary)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
20 Metformin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Gynaecology and Endocrinology only
  • RNOH:
    • Non-formulary
  • UCLH:
    • No restriction stated
  • WH:
    • Non-formulary
06.01.02.02 Metformin modified release 

Provider notes

  • NMUH:
    • Only to be considered in patients on normal release metformin in whom gastrointestinal side effects prevent continuation of treatment
    • See link below
  • RFL:
    • Only to be considered in patients on normal release metformin in whom gastrointestinal side effects prevent continuation of treatment
    • See link below
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Only to be considered in patients on normal release metformin in whom gastrointestinal side effects prevent continuation of treatment
    • See link below
04.07.02 Methadone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For use in pain - restricted to pain and palliative care teams
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.10.03 Methadone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary - see link below
  • RFL:
    • See links below
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Mixture 5 mg/5 ml. Injection 10mg/1ml. Only
03.09.01 Methadone linctus 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to palliative care team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • CD = Controlled drug. The Misuse of Drug Regulations apply and all legal requirements need to be met eg outpatient prescriptions and TTAs should state the total amount of drug prescribed in words and figures. For further details see the BNF.
05.01.13 Methenamine Hippurate 

Approved for recurrent UTIs in adults who have experienced ≥ 2 UTIs in the last 6 months, or ≥ 3 in the last 12 months (JFC April 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per above JFC agreed indication  
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.02.02 Methocarbamol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.03 Methotrexate 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • 2.5mg tablets must be prescribed for non-malignant indications
    • See pharmacy policy for the safe dispensing of methotrexate
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See link below
13.05.03 Methotrexate 

NOTE: There is more than one monograph for Methotrexate, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    •  See link below
  • RFL:
    •  All patients must be issued with a methotrexate monitoring booklet which must be reviewed at each dispensing
    • Only 2.5mg tablets to be prescribed
    • See pharmacy policy for the safe dispensing of methotrexate
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.03 Methotrexate injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
20 Methotrexate injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Zlatal is stocked. This is a licensed preparation, but it is not licensed for use in ectopic pregnany
  • RFL:
    • See local protocol
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Methotrexate SC / IM injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

The licensed routes of administration for parenteral preparations vary—further information can be found in the product literature for the individual preparations.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Metoject brand available in a variety of strengths.
  • RNOH:
    • Rheumatology Consultants ONLY
    • Metoject and Nordimet (if autoinjector required) brand
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
03.12 Methotrexate tablets 

NOTE: There is more than one monograph for Methotrexate, click here to search for formulary status and its use for other indications. 

Approved for severe asthma. Restricted to the Severe Asthma Service  (September 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.12 Methotrexate tablets 

NOTE: There is more than one monograph for Methotrexate, click here to search for formulary status and its use for other indications. 

Approved for sarcoidosis after failure of steroids  (JFC April 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the Sarcoid Clinic
    • Only 2.5mg tablets to be prescribed
    • See pharmacy policy for the safe dispensing of methotrexate
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See indication above
08.01.03 Methotrexate tablets 

NOTE: There is more than one monograph for Methotrexate, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Not Appliable
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Methotrexate tablets 

NOTE: There is more than one monograph for Methotrexate, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See links below.
  • RFL:
    • 2.5mg tablets only
    • All patients must be issued a methotrexate monitoring booklet which must be reviewed at each dispensing
    • See pharmacy policy for safe dispensing of methotrexate
  • RNOH:
    • Restricted for Rheumatology Consultants ONLY
    • 2.5mg tablets ONLY
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®

Provider notes

  • NMUH:
    • Non-formulary.
  • RFL:
    • Restricted to renal team only (3rd line)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Methoxypsoralen 

Provider notes

  • RFL:
    • Approved for use by dermatology
    • 8-methoxypsoralen tablets 10mg, gel 0.005% and bath lotion 1.2% available
    • 5-methoxypsoralen tablets 20mg available
13.08.01 Methyl-5-Aminolevulinate Metvix®

Secondary care notes

  • RFL approvals
    • First line treatment for Bowen's disease and second line treatment for AK and BCC
02.05.02 Methyldopa 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.04 Methylphenidate Hydrochloride Medikinet®XL

Approved for ADHD (JFC February 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As above
04.04 Methylphenidate Hydrochloride Concerta®XL

Approved for ADHD (JFC February 2019).

Provider notes

  • NMUH:
    • Non-formulary Restricted to the Child & Adolescent Mental Health Service only.
  • RFL:
    • Restricted to the Child & Adolescent Mental Health Service only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA98 / CG87
04.04 Methylphenidate Hydrochloride Equasym®XL

Approved for ADHD (JFC February 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As above

&